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Abstract 
 Tumor cell vaccination is a promising strategy for patients with primary brain 
tumors.  Cell-derived vaccines have been developed and tested in patients with many 
cancers, resulting in objective responses in a minority of cases.  Tumor cells are often 
harvested from tissue culture, where phenotype can shift in response to many factors.  
Oxygen affects expression of thousands of genes, yet its impact on immunogenicity in 
culture was unknown until recently.  Compared to atmospheric oxygen levels, 
physiologic (5%) oxygen increases the adjuvant properties and efficacy of glioma 
vaccines.  These studies determined the impact of oxygen on cell-mediated and humoral 
immunity with regard to its potential for improving efficacy in brain tumor patients.  
Immunogenicity and oxygen were first investigated over a broader oxygen range, with 
5% oxygen still yielding the greatest extension of survival.  With the effort to maximize 
immunogenicity, primary autologous meningioma cells from pet dogs were cultured in 
5% oxygen for vaccine production. Dogs vaccinated with lysate/adjuvant vaccines based 
on these cells induced robust antibody responses and survived a median of three-fold 
longer than historic controls.  Further studies in mice led to the discovery that glioma 
cells cultured in 5% oxygen upregulated a “danger” signal, annexin II.  Monomeric 
annexin II enhanced dendritic cell cross presentation, CD8 T cell priming, and extended 
survival of murine breast carcinoma and plasmacytoma. Enriching for endogenous 
danger signals by decreasing tissue culture oxygen is a simple means to enhance the 
immunogenicity of brain tumor cultures.  
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CHAPTER ONE  
INTRODUCTION1 
 
Brain Tumors: Epidemiology and Types 
 It is estimated that there are 688,000 people living with a primary brain or central 
nervous system tumor, of which 124,000 are malignant (1).  Primary brain tumors can be 
divided into six histological categories, in order of decreasing incidence: (1) tumors of 
the meninges, the membranes surrounding the brain and spinal cord (35%); (2) 
neuroepithelial tumors, including glial, choroid plexus, and primitive neuronal tumors 
(34.5%); (3) tumors of the sellar region such as pituitary adenomas and 
craniopharyngiomas (13.5%); (4) tumors of the cranial and spinal nerves (8.7%); (5) 
unclassified tumors such as hemangioma (5.5%); and (6) primary CNS lymphomas 
(2.5%) (2).  Due to the high prevalence of clinically aggressive glioma and meningioma, 
alternate approaches for these tumors have potential to improve survival and quality of 
life in a large number of patients.  
Meningiomas  
 Meningiomas are derived from meningothelial arachnoid cap cells, which reside 
in locations where the cerebrospinal fluid is resorbed into the systemic circulation (3).  
Meningiomas impair neurologic function by compressing the brain, leading to seizures as 
                                                 
1 Reprinted in part with permission from Andersen BM and JR Ohlfest. “Increasing the 
efficacy of tumor cell vaccines by enhancing cross priming.” © Elsevier Inc. Originally 
published in Cancer Letters. 2012. Dec 28;325(2):155-64. PMID: 22809568 
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the presenting symptom in most cases (4).  Initial workup involves imaging pre- and –
post-contrast MRI, which typically reveals meningiomas as homogenously contrast-
enhancing since they are usually outside the blood-brain barrier (5). A connection to the 
meninges is often seen, which is known as a “dural tail.” 
 Meningiomas are classified by their typical histologic appearance of fusiform 
cells that are positive for epithelial membrane antigen (EMA) and negative for glial 
markers such as glial fibrillary acidic protein (GFAP) (6).  The World Health 
Organization assigns a grade of I-III to meningiomas to predict outcomes.  Grading is 
based on the number of mitotic figures, invasion into brain, histologic subtype, and the 
presence of necrosis (7, 8).  While 90% of meningiomas are benign tumors that are cured 
by surgical resection (9), recurrent, atypical (WHO II), and malignant (WHO III) 
meningiomas affect over 6,000 patients a year (2, 9).   
 Several molecular aberrations have been associated with meningiomas.  Loss of 
heterozygosity of chromosome 22q occurs in 60% of meningiomas, and early steps in 
tumorigenesis are thought to be due to loss of the NF2 gene (3).  The precise mechanism 
of tumor formation is not known.  NF2 encodes the protein Merlin, which is involved in 
Hippo signaling and contact inhibition (3).  Recent genomic analysis has divided 
meningiomas into NF2 and non-NF2 tumors, with NF2 loss-of-function tumors more 
likely to be aggressive.  Other mutations identified were in the TRAF7, AKT, and SMO 
genes, with SMO mutations in non-NF2 meningiomas arising from the skull base (10).  
Numerous other gene mutations have been identified including those in angiogenic 
pathways, MAP kinase signaling, and many growth factors and cytokines (3). 
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 The standard-of-care treatment for all meningiomas is maximal surgical resection, 
which is followed by radiation in the case of WHO II and III tumors.  Brain-invasive 
meningiomas become “a disease of the entire brain,” since tumor cells intermix with 
parenchymal architecture, bearing a worse prognosis, (7, 11).  No treatments have been 
established in randomized trials for salvage therapy for meningioma, although radiation, 
stereotactic radiosurgery, and hydroxyurea are commonly used (4, 9, 12, 13, 14).   
 Gliomas 
 Gliomas are neoplasms thought to arise from glia and are malignant in 67% of 
patients (2, 11).  While lower grade gliomas often present with seizures, high-grade 
gliomas present more often with focal neurologic dysfunctions such as hemiparesis, 
visual deficits, hemi-sensory loss, or aphasia (15).  The highest grade (WHO IV) and 
deadliest glioma is glioblastoma multiforme.  Median age of newly diagnosed 
glioblastoma patients is 65, whereas those of WHO grade III astrocytomas and 
oligodendrogliomas are 41 and 48, respectively (16, 17).   
 Appearance of gliomas on MRI is variable, with the most classic glioblastomas 
showing a “ring” enhancement pattern following contrast administration.  The “ring” is 
due to disruption of the blood-brain barrier by the tumor, with a central necrotic region 
(18).  WHO grade III astrocytomas and oligodendrogliomas have variable appearance on 
MRI, with irregular, heterogeneous contrast enhancement (19).  As many as 30% of cases 
of these two grade III tumors, however, are non-contrast-enhancing (20).  Lower grade 
astrocytomas and oligodendrogliomas are usually non-contrast-enhancing, as the blood-
brain barrier is still intact, with the tumor lying behind this barrier (15). 
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 Glioblastomas can arise from previously lower-grade gliomas (secondary) or arise 
de novo (primary).  Virtually all low grade tumors will progress to grade III or IV 
(malignant) status over time (15).  Malignant gliomas (WHO grade III and IV) can be 
further broken down into histologic subtypes after the normal cells they are thought to 
resemble, the most common being astrocytoma and oligodendroglioma.  Grade III 
astrocytomas can be identified by expression of GFAP, increased cellularity, nuclear 
atypia, increased mitotic activity, and micro-vascular proliferation (6).  Glioblastomas 
(WHO grade IV astrocytomas) also bear these characteristics except that they have a less 
differentiated, pleomorphic morphology, in addition to “pseudopallisading necrosis” (6, 
15).  Grade III oligodendroglioma histologically appear to have a “fried egg” appearance, 
basophilic cells that are consistent in appearance, with a cleared cytoplasms (21).  
Oligodendrogliomas contain calcifications more often than astrocytomas, and often with 
finely branching capillaries known as “chicken wire vasculature (6).” 
 Considerable progress has been made with regard to understanding of genetic 
aberrations of gliomas.  The Cancer Genome Atlas reported gain of function in the 
Ras/receptor tyrosine kinase pathway in 88%, loss of function of P53/MDM2 signaling in 
87%, and loss of Retinoblastoma signaling in 73% of glioblastomas (22).  Molecular 
subtyping of high-grade gliomas revealed considerable molecular heterogeneity and 
dramatically different prognoses, despite similar histologic appearance (23).   The 
proneural gene expression profile bears a positive prognosis, with median survival more 
than double that of the mesenchymal and proliferative subtypes (23).  Considerable 
progress has been made in understanding and targeting the initiating events of proneural 
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glioblastoma, which is most often in younger patients with secondary glioblastoma (24-
27).  In this subtype, an oncometabolite, 2-hydroxyglutarate, is produced by mutant 
isocitrate dehydrogenase 1 (IDH1R132H) (24-28).  As this mutation is found in many grade 
II and III astrocytomas and oligodendrogliomas, decreasing production of this 
oncometabolite could prevent transformation to a higher grade (24-27).  Moreover, 
oligodendrogliomas with deletion of chromosomes 1p and 19q are known to have better 
response to chemoradiotherapy and better prognoses (29). 
 High-grade gliomas are treated by surgical resection followed by neoadjuvant 
chemoradiation therapy, consisting of temozolomide alkylating chemotherapy and focal 
radiation (30).  Median survival for WHO grade IV glioma is approximately 14.6 months, 
with only a few patients living longer than five years (31).  Persons whose high-grade 
gliomas recur receive treatment with the monoclonal antibody targeting VEGF, 
bevacizumab (32) or salvage chemotherapy such as the mustard agent lomustine (33). 
Patients survive a median of 8 months following these treatments (34).  Therefore, 
glioma as well as meningioma patients with aggressive disease need more effective 
treatments to extend survival and improve or maintain their quality of life.  
Cancer Vaccines: Historical Perspective and Successes 
 The less effective aseptic surgical techniques of 18th century medicine led to post-
operative tumor resection infections, ultimately revealing that the immune system is 
capable of eliminating tumors.  In the 1890’s, William Coley, a surgeon in New York, 
noted, in records dating back to the 1700s, that cancer patients with post-operative 
streptococcal infections sometimes had spontaneous regression of their tumors.  He 
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therefore injected Streptococcus and Serratia bacteria into his patients’ tumors, inducing 
regression in more than 10% of cases (35, 36). 
 120 years later, basic knowledge of cancer, immunology, and vaccinology has 
brought about many cancer immunotherapy approaches.  Tumors express self- and neo-
antigens from their aberrant genetic programs, distinguishing themselves 
immunologically from normal tissue.  As tumors enlarge, they evade and suppress the 
immune system, often overcoming spontaneous immune responses (37).  Vaccines aim to 
activate adaptive immune responses by providing antigens in conjunction with an 
immune stimulus or adjuvant.  Thousands of cancer patients have been treated with tumor 
cell-based vaccines, with evidence of efficacy.  Provenge is the first United States 
FDA-approved cancer vaccine, intended for men with metastatic castration-resistant 
prostate cancer.  It consists of autologous antigen presenting cells incubated with a 
protein fusion of prostatic acid phosphatase and granulocyte-macrophage colony-
stimulating factor (GM-CSF; (38).  A recent phase III trial that included over 400 patients 
extended median survival by 4.1 months (25.8 versus 21.7 months in placebo; p=0.02; 
ref. (39).  Although subunit and peptide vaccines have several advantages, a recent meta-
analysis accounting for 3,444 patients in 173 clinical trials indicated that tumor cell-based 
vaccines had higher response rates (~8%) than vaccines consisting of synthesized 
antigens (~4%) (40).  Cell-based approaches likely provide a diverse pool of antigens that 
can trigger concurrent CD4 and CD8 T cell responses with tumor-reactive antibodies, and 
thus broader antigenic coverage.   
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  Vaccines consisting of materials from cultured tumor cells show some success 
but have yet to receive approval in the US.  Melacine is a melanoma vaccine consisting 
of lysates from two allogeneic melanoma lines combined with the adjuvant DETOX.  
When given to 198 patients in phase II/III trials, it induced five complete responses and 
seven partial responses (overall response rate 6.0%; ref. (41).  While the overall response 
rate was similar to (if not lower than) that of Coley, four patients with complete responses 
were still alive and disease free at 7-10 years post-treatment, implying long-term disease 
control through memory responses (41).  Interestingly, retrospective analysis showed that 
the response rate was 38% in patients expressing HLA-A2 and HLA-C3 (41).  With a 
better safety profile and comparable complete response rate to chemotherapy or high-
dose IL-2, Melacine was approved for treatment of metastatic melanoma in Canada.  A 
tumor cell lysate vaccination known as Reniale improved renal cell carcinoma 
outcomes in a recent phase III study (42).  Nephrectomy was performed in patients with 
organ-confined disease, and lysate vaccines were produced from autologous tumor cells 
stimulated with IFNγ.  Reniale led to increased time-to-progression and survival 
compared to nephrectomy monotherapy (Hazard Ratio=1.58, 95% C.I. = 1.05 to 2.37 at 5 
years; (42).  Recently, 10-year follow-up survival of patients with aggressive stage III 
disease was 58.9% in patients given Reniale versus 36.2% in surgery monotherapy 
(43).   
Brain Tumor Cell Vaccines 
 Despite the improvement of survival in brain tumor patients over the last decade, 
these tumors often continue on a devastating course.  Therefore, great hope for brain 
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tumor care has sprung from the early proof-of principle evidence in clinical trials testing 
brain tumor cell-based vaccines.  Yamanaka and colleagues reported efficacy from 
treatment of 24 recurrent glioma patients with intratumoral and/or intradermal injection 
of autologous glioma lysate-pulsed dendritic cells.  One patient had a partial response 
(>50% volume reduction), three had “minor” shrinkage of tumor (25-50%), and ten 
others exhibited stable disease lasting at least four months (44).  Moreover, seven of these 
fourteen patients who benefitted from the vaccine showed increases in tumor-reactive T 
cells by ELISpot (44).  Another more-recent phase II study of autologous tumor-pulsed 
dendritic cell vaccination achieved an impressive 54% three-year survival.  Responding 
patients showed increased CD8 T cells into tumors following vaccination (45).  While 
these results have drawn enthusiasm and hope, overall response rates must be improved 
to benefit larger patient populations.  And to increase overall response rates, we must 
scrutinize the mechanisms by which brain tumor cell vaccinations act.  
Mechanisms of Anti-Brain Tumor Immunity 
 There are many key effector cells and molecules involved in anti-brain tumor 
responses.  While many cells of the innate and adaptive immune system help eliminate 
tumors, the adaptive arm, comprised of the B and T lymphocytes, is considered the most 
capable of tumor elimination and long-term tumor control (46).  The advantages of 
polyclonal antigen-specificity and memory make them more precise, adaptable to 
resistance mechanisms, and longer-lasting than conventional chemotherapies (47).  
Understanding the mechanisms of B and CD8 T cell activation following vaccination will 
help to identify the key hurdles to successful brain tumor immunotherapy.   
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Dendritic Cells: Immune Sentinels and Presenters of Tumor Vaccine Antigens to 
CD8 T Cells 
 Antigen presentation to CD8 T cells is imperative for igniting a tumoricidal 
response (48), and dendritic cells (DCs) present these antigens more efficiently than any 
other cell type (49).  Upon injection of tumor cells or cell components, DCs take up these 
materials and process them as they patrol the skin and secondary lymphoid organs.  For 
optimal priming of CD8 T cells, DCs must provide three signals: (i) antigen cross-
presented in the form of a peptide—MHC I complex; (ii) co-stimulatory molecules on 
their surface; and (iii) secreted cytokines (50).  Additional complexities, such as the DC 
subset of interest (51), DC trafficking (52), tissue of antigen challenge (53), and optimal 
CD4 T helper cell differentiation (54) also profoundly influence CD8 T cell activation.  It 
is now clear that once optimally activated, CD8 T cells can specifically target brain 
tumors in human patients (55).  
Cross Priming in Active Immunotherapy: Activating Tumoricidal CD8 T cells 
 The “altered self” hypothesis states that CD8 T cells distinguish self from non-self 
(such as tumor neo-antigen) by recognition of the complex of peptide antigen and the 
major histocompatibility complex (MHC) I (56, 57).  Each CD8 T cell undergoes somatic 
mutation to develop a unique T cell receptor specificity for a given peptide sequence and 
MHC I (58).  At first, immunologists debated how and where peptide—MHC I complex 
formation occurs.  Does the CD8 T cell recognize the MHC I-peptide complex on the 
surface of the injected tumor cell or cell fragment, or do antigens transfer to another cell?  
While both scenarios are possible, Michael Bevan demonstrated that transfer of antigen 
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to a host immune cell occurred (59).  He coined the term “cross priming” to describe the 
process by which exogenous antigens are uptaken and loaded on MHC I rather than 
expressed directly (59).  
 Identifying and understanding the function of the cell type doing the cross priming is 
crucial to understanding how to best elicit a CD8 T cell response.  The DC was identified 
by Ralph Steinman and Zanvil Cohn in 1973 (60).  It took ten years from their discovery 
to confirm the DC as the most potently cross priming cell, as DC depletion resulted in the 
drastic reduction of killing in the mixed leukocyte reaction (49).  
 What features of DCs make them adept at cross priming?  The most crucial is known 
as signal one, or cross presentation. Antigens are recognized and taken up by DCs 
through endocytosis, macropinocytosis, or phagocytosis, degraded into peptide fragments 
8-10 amino acids in length that are loaded onto MHC I and shuttled to the cell surface.  
The mechanisms of cross presentation are partially understood, but recent studies indicate 
that immune stimuli such as those discussed later induce changes in the routing of 
antigen.   
 While cross presentation of tumor antigens is necessary for CD8 T cell-mediated 
tumor rejection, it also requires additional DC—CD8 T cell signals.  Early studies that 
sought to reconstitute T cell priming were hampered by unresponsiveness of T cells after 
mono-stimulation with MHC and peptide.  Jenkins and Schwartz demonstrated that 
antigen-loaded antigen presenting cells that were chemically fixed presented peptide to 
CD4 T cells, but these T cells could not proliferate without a co-stimulatory short-range 
signal (61, 62).  Complementary to these findings was the discovery that at steady state, 
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DCs induce tolerance to CD8 T cell antigens (63).  The missing signals in the case of 
CD4 and CD8 T cell activation were CD80 and CD86, DC-expressed ligands for the 
CD28 co-stimulatory receptor on T cells.  CD28 signaling results in the amplification of 
the TCR signal, inducing a proliferative response and IL-2 synthesis within the activated 
T cell.  Following CD28 signaling, additional co-stimulatory receptor-ligand interactions 
are important in driving optimal T cell activation including, ICOSL-ICOS, OX40-OX40L 
and CD137-CD137L among others (46).   
 Attempts at recapitulating cross priming in vitro by incubating naïve CD8 T cells 
with microbeads containing MHC I-peptide complexes and CD80/86 were partially 
successful (64).   These stimuli triggered several rounds of cell division and temporary 
effector function, but cells were unable to reach full effector function, survive, and 
develop memory (64).  When interleukin 12 (IL-12) or interferon alpha/beta (IFNα/β) 
were added to these cultures, however, full CD8 activation was successful (64).  Further 
studies of adoptive transfer of IL-12R+/+ CD8 T cells into IL-12R-/- recipients 
demonstrated that the IL-12R on CD8 T cells was sufficient for this signal to occur (65).   
 Tumor cell vaccines should therefore stimulate the production of IL-12 or IFNα/β 
to provide adequate signal 3 for optimal cross priming.  IL-12 secretion in vivo can be 
stimulated when CD4 T cells present CD40L to CD40 expressed by DCs, a key trigger 
for IL-12 release (66).  Multiple methods of inducing signal three have shown promise, 
including providing the exogenous cytokine via genetic engineering (e.g., IL-12 
producing tumor cells) (67, 68) or co-injection of recombinant cytokine (69). The use of 
type I interferon-promoting adjuvants as inducers of signal 3 show promise for tumor cell 
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vaccine therapy, as they augment signals 1 and 2 by enhancing DC maturation.  
The Activation of the Tumor-Reactive B Cells and Antibodies 
  B cells are lymphocytes that each express a somatically mutated, unique 
membrane-anchored antibody, known as the B cell receptor (BCR) .  Each B cell clone is 
therefore responsive to a specific cognate antigen and capable of initiating antibody 
responses.  B cells develop in the bone marrow, but they reside in the follicles of lymph 
nodes in their naïve state, awaiting direct contact with tumor cell antigens from the 
lymphatic drainage (70).  
 The molecular specificity of B cells arises from the specific antigen to which their 
membrane-bound antibodies, are tuned.  Antigen-BCR binding is the first of two required 
signals for full activation that leads to antibody formation and development of a humoral 
memory response.  Unlike CD8 T cells, B cells require no antigen presenting cells to 
classically engage antigen with their BCR.  The size of B cell epitopes is thought to be 
more variable, although still a small fraction of the originating molecule.  Epitopes for 
BCRs include proteins, carbohydrates, lipids, and nucleic acids.   
 Like CD8 T cells, B cells require costimulatory and cytokine signals for full 
activation.  Antigen binding to BCRs triggers internalization and subsequent digestion of 
antigen into peptide fragments.  Some fragments bind MHC class II and are presented in 
the peptide—MHC II complex on the surface of the B cell.  Simultaneous to this antigen 
processing, the B cell begins to migrate to the edge of the follicle bordering the T cell 
zone (71).  Costimulation arises when a CD4 T helper cell recognizes its cognate 
peptide—MHC II complex on the surface of the B cell (72), after which (T cell) CD40L--
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CD40 interaction are required for activation of the antibody response (73-75).  As well, 
CD4 TCR engagement triggers local cytokine (IL-2, IL-4, IFNˠ and IL-5) production by 
the helper cell to act locally on the B cell (76).  Upon receiving these three signals, B 
cells undergo class switch recombination to produce a specific isotype of membrane-
bound antibody/BCR (IgM to IgG, IgA, or IgE).  B cells then differentiate into one of 
three fates: (1) short-lived plasma cells, that secrete antibodies (77); (2) germinal center B 
cells, which mutate their BCRs to evolve higher affinity receptors for eventual 
differentiation into memory B cells or long-lived plasma cells (76); or (3) long-lived 
memory B cells (78).  
 After B cell activation following tumor cell vaccination, antibodies then circulate 
through the blood and bind to tumor antigens within the blood or at the tumor.  Antibody 
binding to intracellular antigens from dead cells may assist in antigen uptake by APCs, 
and surface binding to living tumor cells can trigger a number of effector activities that 
result in tumor cell death.  Effector functions triggered by antibody binding to cognate 
epitope include: (a) neutralization of the target protein’s function (79), (b) phagocytosis 
leading to clearance and/or adaptive immunity (80, 81), (c) complement dependent 
cytotoxicity (82, 83) (d) chemo-attraction of leukocytes, or (e) antibody-dependent cell-
mediated cytotoxicity (83).  The isotype of a given antibody determines the structure of 
Fc region and thus the recognition of the Fc region by specific Fc receptors.  Class 
switching of antibodies by B cells (for example, from IgM to IgG) alters the antibody Fc 
regions and thus the effector functions that can impact the cell bearing the epitope.  
Molecular Pattern Detectors: Keys to Dendritic and B Cell Activation  
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 Under steady-state conditions DCs are immature.  If they encounter antigen in 
isolation, tolerance ensues due to weak signal 1 and the lack of signals 2 and 3 to fully 
activate T cells (63).  To mature DCs in culture and break tolerance, early DC 
immunologists added medium from gamma globulin-treated monocytes, which operated 
indirectly to trigger cytokine release (84, 85).  In vivo, however, DCs sense the local 
cytokine milieu in combination with molecular patterns of pathogens and tissue damage.   
 The discovery of Toll, a gene in Drosophila associated with immunity from 
fungal infection (86), marked the explosion of the molecular pattern field.  Toll-like 
receptors (TLRs) were found to be sensors of molecules conserved among many species 
of pathogens.  At the same time, DC pioneers discovered maturation could occur through 
addition of lipopolysaccharide, a cell wall component of gram-negative bacteria (87).  
TLRs thus link the innate and adaptive immune systems through the maturation program.  
Upon ligation of their leucine rich repeat-containing extracellular domains with 
pathogen-associated molecular patterns (PAMPs), TLR cytosolic domains cluster 
together (sometimes with a different TLR) which allows adaptor proteins to bind and 
signal through NFκB and AP-1 (88).  Within minutes of recognition of a microbial 
pattern, multiple signal transduction arms (transcriptional and post-translational) enact 
secretion of pro-inflammatory cytokines and increased surface expression of pre-made 
co-stimulatory and MHC molecules (89).  Importantly, co-administration of TLR ligands 
with antigens increases cross presentation (signal 1) by altering the intracellular 
processing route of antigen (90).   
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 TLR ligands, in particular the TLR9 agonist hypomethylated cytosine-
phosphodiester-guanine (CpG) oligonucleotides from bacteria, also induce the activation 
of B cells when co-delivered with antigen (91).  The potency of CpG stimulation is often 
strong enough to induce plasma cell differentiation in the absence of CD4 helper cells 
(92), but also increase B cell proliferation (91), class-switching (93), upregulation of 
costimulatory molecules (94), and cytokine release (91). 
 TLRs are joined by many receptors that sense PAMPs and other patterns, and 
all these receptors have been appropriately named pattern recognition receptors (PRRs).  
Diverse molecular structures are therefore capable of working alone or in combination to 
activate dendritic and B cell activation enhance the adaptive immune response against 
brain tumors.  
Death and Danger Sensors in Dendritic Cells and B cells 
 All cells undergo stress responses in situations of environmental hostility, 
including mechanical trauma, nutrient starvation, temperature extremes, DNA damage, 
infection and hypoxia.  These insults result in the release of pre-made molecules or the 
production of stress-related molecules that are subsequently released.  Active or passive 
death can lead to the release of “danger” molecules, and growth conditions before death 
directly impact the expression of molecules to be released by these processes.  Numerous 
studies document the production and biologic function of stress-associated molecules in 
malignant and non-malignant cells.  Such studies have laid the foundation for identifying 
the internal arsenal of molecules within tumor cells that may enhance the anti-tumor 
adaptive immune response under the proper conditions.   
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 Shortly after the discovery of TLRs, Matzinger and Fuchs proposed that the 
concept of the immune system’s discrimination between self and non-self was inaccurate 
(95, 96).  After all, this dichotomy failed to explain autoimmunity (95, 96).  They argued, 
rather, that the immune system’s “switch” was sensitive to danger signals, be they from 
pathogens or from pathologically dying self-cells (95, 96).  Endogenous danger signals 
from stressed, dying, or dead cells were termed the damage-associated molecular patterns 
(DAMPs), and these molecules are largely detected by the same pattern recognition 
receptors as PAMPs (97).  Since their inception, their identification has been provocative, 
arduous and controversial.   
 In 2000, Rock and colleagues reported the intrinsic adjuvant activity of 
cytosolic proteins within multiple syngeneic cell lysates.  The lysates enhanced CD8 T 
cell killing following co-injection with model antigens such as chicken ovalbumin (98).  
These findings reveal many key properties of DAMPs:  
1. Cells passively release pre-made DAMPs upon instantaneous death (necrosis) 
or apoptosis;  
2. UV irradiation, chemotherapy, or heat shock can boost adjuvant activity; and 
3. Malignant and non-malignant cells can release DAMPs.  
 Shortly thereafter, B cell activation was observed by synergy between BCR and 
self-DNA-mediated TLR9 activation in a murine model of rheumatoid arthritis (99).  
These studies were corroborated by similar findings in human B cells (100).   
 In addition, these studies set the stage for the molecular identification of 
DAMPs themselves.  We now know that DAMPs constitute a diverse group of proteins 
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and non-proteins that activate TLRs, nod-like receptors, purinergic receptors, and 
scavenger receptors (101, 102).  Excellent reviews on the many effects on sites of 
inflammation abound (101, 102).  Relevant to the use of tumor cell vaccines are the 
effects of these molecules on the adaptive immune response, and how tissue culture can 
enrich for these molecules.  
 The currently characterized DAMPs make up diverse groups of molecules from 
all cellular compartments.  Most important to cross priming are their target receptors, 
known for their pattern recognition and connections with signals 1,2, and 3.  Less-well 
studied DAMP sensors are the C-type lectin receptors (CLRs), RIG-I-like receptors 
(RLRs) and nod-like receptors (NLRs).  They synergize with TLRs, and their effects on 
cross priming are less well understood.  These receptors could exert powerful biologic 
effects and demand attention for their potential as tumor vaccine targets. 
 CLRs are scavenger receptors that serve as a recognition and entry point for 
specific glycosylated antigens (103).  Closely linked to entry is the endocytic routing of 
an antigen taken up after binding CLRs; therefore, recognition by CLR significantly 
influences in the intracellular route of the antigen within the cell.  As tumor antigens are 
frequently alternatively glycosylated (104), the role of CLRs in tumor antigen processing 
is a potential mechanism for selective priming against tumor antigens. For example, some 
CLRs expressed by DCs such as DC-SIGN recognize malignancy-associated 
glycosylation patterns selectively (105).  As discussed later, CLR binding by itself often 
leads to tolerance (106), but its potential to contribute to cross priming via antigen uptake 
and routing in combination with other maturation stimuli is relatively unexplored.  
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 RLRs and NLRs are cytosolic receptors that bind diverse ligands, including 
single- and double-stranded RNA, double-stranded DNA, and cathepsin enzymes that are 
released as a result of phagosome rupture.  These receptors play an integral part in 
vaccine components empirically established in the past, ranging from live attenuated 
viruses to aluminum (107, 108).    
 Providing ligands for these pattern recognition receptors in purified form and in 
combination with tumor antigens in various forms has yielded inconsistent results.  An 
alternative to this exogenous source is to make use of tumor cells in culture that produce 
their own ligands for pattern recognition receptors.  A wealth of literature indicates there 
are many avenues one might use to boost cross priming through induction of these 
endogenous ligands.  Understanding how to optimize the production of the molecule or 
molecules that best enhances adaptive immunity will not be a trivial task; however, such 
knowledge is required to move the field forward and enhance the efficacy of tumor cell 
vaccines. 
Rational Design of Tumor Cell Vaccines Aimed at Inducing Adaptive Immunity 
 Recent technology has enabled the identification of many tumor-associated 
antigens and the production of synthetic antigen (e.g., peptide, subunit) vaccines (109, 
110).  Despite these efforts, to date tumor cell-based vaccines have triggered double the 
response rate (~8%) relative to vaccines consisting of synthesized antigens (~4%) (40).  
At least part of this difference in success lies in the challenge of variable antigen 
expression among cells in a given tumor and between tumors of different individuals.  
Vaccinating with too few antigens will result in selection of antigen loss variants and 
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tumor progression.  This has been elegantly demonstrated in animal models by Schreiber 
and colleagues, indicating loss of single immunodominant CD8 T cell epitope can be 
adequate for immune escape (111).  In humans, a notable example includes glioblastoma 
patients vaccinated with a peptide from epidermal growth factor receptor variant III 
(EGFRvIII), in which recurrent tumors stopped expressing the protein despite being 
positive at enrollment (112).  To induce a broad response, vaccines must provide 
adequate quantities of multiple antigens (40).   
 At the time of writing this thesis, clinicaltrials.gov contained over 1,000 search 
hits for “tumor cell vaccines,” the majority of which place great faith in ex vivo tumor 
cell culture to provide such a diverse pool of antigens.  As in the past, the success or 
failure of these trials will likely depend on all-too-often neglected aspects of tissue 
culture and vaccine production that affect the three required signals for B and CD8 T cell 
activation.  With new knowledge of endogenous adjuvants, working stepwise is the most 
rational approach for moving beyond the current modest success.   
 Tissue culture differs from in vivo tissues in many aspects, including nutrient 
supply, dimensionality of substrate, and oxygen tension.  These differences result in 
many changes, including divergence in antigen expression, decrease in heterogeneity, and 
loss of stromal cells to which immunization can target.  Studies such as that by Lee and 
colleagues have sparked optimism that tissue culture can be more immunogenic once we 
identify crucial factors that govern cross priming and B cell activation.  They observed 
dramatic and irreversible gene expression changes in glioma cells grown in serum-
containing media (113).  Culturing cells in neural stem cell (NSC) media with basal 
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fibroblast growth factor and epidermal growth factor resulted in a relatively preserved 
phenotypic and genotypic profile (113).  When glioma cells from NSC media were used 
for vaccine immunotherapy of glioma-bearing mice, they resulted in superior tumoricidal 
CD8 T cell responses and increased survival compared to vaccines from serum-
containing culture (114).  
 Tissue culture is therefore a double-edged sword in that it risks inducing an 
artificial phenotype, yet proper manipulation may result in a vaccine superior to the 
phenotype of the tumor itself.  As discussed below, oxygen tension in culture can enrich 
for antigen and adjuvant expression during tumor culture (115).   
Oxygen 
 Oxygen (O2) regulation is crucial for survival of metazoan organisms.  In the 
mammalian body, O2 delivery homeostasis occurs through sensing of the molecule in the 
blood vessels in the lungs and kidneys, but all cells sense changes in oxygenation (116, 
117).  O2 sensors affect gene expression, phenotype, and behavior in response to changes 
in oxygen availability in a graded and temporally complex manner (118).  Upon a 
decrease in O2, neurons and glia react through short- and long-term mechanisms to adapt 
and attempt to restore O2 supply (119).  On the scale of seconds to minutes, decreases in 
O2 cause diminished in neuronal and glial excitability through altered membrane channel 
conductivity such as that of TASK potassium channels (120).  As well, short-term 
suppression of gene transcription and translation occurs to conserve energy (121, 122).  
Longer-term adaptation to hypoxia results in changes in gene expression through redox-
sensitive transcription factor activity, such as that of nuclear factor kappa B (NFkB), 
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activator protein 1 (AP-1), early growth response protein 1 (EGR-1), and hypoxia-
inducible factors (HIFs) (123-125). It is believed that hundreds of genes transcriptionally 
regulated by O2, but these changes vary greatly among cell types (126).  
 The best understood cell-autonomous O2 sensors are the HIFs, whose alpha 
subunits are targeted for degradation in normoxia (127).  Upon a decrease in O2 below 
~6%, which is within the physiologic range of brain parenchyma (128), degradation 
ceases, and HIFs become active as transcription factors (129).  HIF-responsive genes can 
be identified by the presence of hypoxia response elements (HREs); however, dozens of 
O2-regulated genes lack HREs and are altered by HIF indirectly or by HIF-independent 
means (130).   
 Oxygen levels within the healthy brain range from 1-5% (128), with levels in 
glioma ranging widely, from 0.1-10 % (131).  HIFs vary in expression level 
exponentially between 1 and 6% O2 (132), but we lack a deep understanding of how 
variability in this activity modulates gene expression and phenotype.  Moreover, tissue 
culture incubators for glioma culture often regulate CO2 but not O2.  As a result, 
atmospheric O2 levels (~20%) induce degradation of HIFs and shift gene expression 
away from that of the tumor in situ (133).   
 Conversely, we recently found that transfer of glioma cells from 20% to 
physiologic (5%) O2 (for at least 2 weeks) led to a drastic shift in gene expression, 
bringing gene expression closer to the tumor in situ (133).  Lowering O2 induced 
increases in expression of HER2, SOX2, EphA2 and IL-13Rα2, all glioma-associated 
antigens with defined CD8 T cell epitopes (134).  Lysates from 5% O2 cultures also 
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primed CTLs with superior tumoricidal functions against gliomas in vitro using primary 
human samples and in vivo using murine models (133).    
 Upregulation of stress-related molecules during hypoxia is a common response 
seen in many cell types (118); however, it was unknown what immunologic effect if any 
would be seen by decreasing O2 from a supraphysiologic to a physiologic range.  
Intriguingly, lysates from 5% O2 possessed unique adjuvant activity (that was absent in 
20% O2 lysates), inducing superior responses to exogenous antigens as measured by CD8 
T cell proliferation and cytokine production (133, 135).  Weekly vaccination of 5% O2 
lysate-containing vaccines resulted in a 41% increase in survival of glioma-bearing mice 
compared to vaccination with lysate from the same cells grown at atmospheric levels 
(135).  Five percent O2 lysate co-delivered to splenic DCs with chicken ovalbumin also 
increased the number of peptide—MHC I complexes on the cell surface, indicating an 
enhancement of cross presentation (signal 1) (135).  In addition, serum from mice 
vaccinated with lysates from 5% O2 reacted with fewer glioma antigens than serum from 
mice vaccinated with lysates from 20% oxygen (135).  Glioma-reactive antibodies were 
not investigated further.  
 These data formed the basis for allogeneic glioma cell vaccines cultured in 5% 
O2 that were recently tested in a phase I clinical trial for recurrent glioblastoma patients 
(NCT01171469; Olin et al., in preparation).  The mechanisms behind O2’s influence on 
immunogenicity and its breadth of application, however, remain unknown.  This thesis 
contributes to brain tumor vaccine immunology by investigating these unknowns. 
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THESIS OBJECTIVES 
1. Determine if decreasing oxygen dose below 5% results in further 
increased adjuvant activity of glioma lysates;  
 2. Assess whether lysate vaccines from low oxygen  are feasible, safe,  
 immunogenic and effective in a preclinical large animal model of  
 aggressive meningioma; and 
 3. Test whether the increased adjuvant activity of glioma lysates from 5%  
 O2 is due to upregulation of a damage-associated molecular pattern. 
. 
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CHAPTER TWO 
 
IMMUNOGENICITY TRANSITIONS IN GLIOMA 
CELLS ACROSS VARIOUS OXYGEN TENSIONS 
 
SUMMARY  
 Immunogenic plasticity is an important feature of cultured tumor cells, as shown 
by the finding that transfer of glioma cells from atmospheric (~20%) to tissue-
physiologic (5%) oxygen (O2) increases their immunogenicity.  While lysate vaccines are 
more effective when made from cells cultured in 5% O2, it was unknown whether 
immunogenicity would increase further as O2 levels were decreased below 5%.  Here, 
studies investigate how immunogenicity varies across a wide range of O2 tensions, 
suggesting that more than one “immunogenicity transition” exists along the O2 
continuum.  These studies first examine the originally described transition from 20% to 
5% O2 that results in the shift from immune-suppressive to immune-stimulatory (133, 
135).  Reversing suppression with desferrioxamine, which increases levels of hypoxia 
inducible factors (HIF) 1α and 2α, suggests that HIFs are at least partially responsible for 
changes in immunogenicity.  Next, we tested whether additional transitions in 
immunogenicity existed as O2 was decreased below 5%.  Cross presentation enhancement 
in vitro by glioma lysates from cells cultured in 2% O2 was increased beyond levels seen 
from 5% O2-derived lysate, but lysate from 1% O2 was less effective.  This second 
immunogenicity transition is likely due to expression changes in many molecules.  For 
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example, we observed an upregulation of heat shock proteins (HSPs) 27 and 70, which 
have been implicated in immune suppression.  Interestingly, preliminary data indicate 
that lysates from cells cultured in 2% O2 fail to extend survival of glioma-bearing 
animals.  These studies predict that immunogenicity varies with O2 tension due to 
multiple variables that affect processes other than cross presentation, and that O2 tensions 
less than 5% may not yield more immunogenic glioma cell vaccines.  Further studies 
therefore focused on lysates from 5% O2.  
INTRODUCTION 
 It is estimated that 1.5% of the genome is transcriptionally regulated by oxygen 
(O2 (126), but how regulation differs in various cell types and finer fluctuations are 
poorly understood.  While many mechanisms underlie O2-induced gene regulation, the 
best-studied sensors, the hypoxia-inducible factors (HIFs), exemplify the complexity of 
expression changes following a shift in O2 level across a relatively narrow range (127).  
HIF protein levels vary exponentially between 1 and 6% O2 (132), the tensions that are 
present within the healthy brain and within gliomas themselves (128, 136).   As HIF 
levels increase, so does their DNA binding activity, with the half-maximal binding 
response between 1.5 and 2% O2 and maximal response at 0.5% O2 (132).  In gliomas, O2 
levels are in constant flux due to variation in vascular diameter, neo-angiogenesis, and 
HIF-driven motility and invasion of glioma cells (137).  We lack a complete 
understanding of how physiologic variations in O2 tension (1-5%) modulate the 
immunogenicity of glioma cells, and this knowledge could lead to more effective glioma 
cell vaccines through manipulation of tissue culture O2.   
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 Decreased O2 is associated with expression changes in many immune modulatory 
molecules that could shift the overall immunogenicity of glioma lysate vaccines.  
Immune modulatory proteins upregulated under decreased O2 include: adenosine, which 
inhibits differentiation of dendritic cells and diminishes T cell responses through many 
mechanisms (138, 139); heat-shock proteins, whose immunogenicity is likely context 
dependent but is currently associated with regulatory T cells and chaperone function 
(140, 141); and the annexin A2—S100A10 tetramer, which activates macrophages and 
probably other leukocytes through TLR4 (142, 143).  Undoubtedly many other molecules 
contribute to immunogenicity in a complex manner, and the convolution of the response 
to change in O2 requires empiric testing.  Head-to-head comparisons of glioma cells in 
20% versus various O2 conditions would increase understanding of low O2-induced 
immunogenicity for improved vaccine efficacy.  
The following experiments tested the immunogenicity of lysates from glioma 
cells cultured in a broad range of O2 tensions.  In addition to O2 tension, pharmacologic 
hypoxia was induced in GL261 glioma cells from which lysates were made.  These 
lysates were then tested for their abilities to increase cross presentation and cross 
priming.  With the understanding that hundreds-to-thousands of molecules are altered 
upon changes in O2, these experiments are a starting point for dissecting dominant 
immunogenic players that call for additional testing to further delineate the mechanisms 
of positive and negative immunogenicity in glioma cell cultures.  They also demonstrate 
the magnitude of immunogenic alterations within a relatively narrow O2 range, and the 
importance of empiric testing of multiple conditions to optimize immunogenicity.  
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METHODS 
Cell culture 
 GL261 murine glioma cells were cultured in media containing DMEM/F12 (1:1) 
with L-glutamine, sodium bicarbonate, penicillin/streptomycin (100 U/mL), B27 and N2 
supplements, and 0.1 mg/mL Normocin.  GL261 cells were supplemented with rhEGF 
and rhFGF (20 ng/mL; Peprotech) semiweekly.  Unless otherwise stated, cells were 
cultured in the indicated O2 tension for at least two weeks before use. For 
desferrioxamine use, compound was added at 130 µM for 48h as previously described 
(144).  
Splenocyte-mediated cross priming 
 For measurement of IFNγ, C57BL/6J splenocytes were plated at a concentration 
of 2 × 105 cells/well in a 96-well plate in complete RPMI 1640 media.  Splenocytes were 
pulsed with 10 µg tumor lysate with or without 10 µg human (h) gp10025-33 peptide 
(KVPRNQDWL) or ovalbumin protein, and incubated for 24 hours.  CD8+ T 
lymphocytes were purified from Pmel (135) or OT1 mouse splenocytes using negative 
immunomagnetic selection according to the manufacturer's protocol (Miltenyi Biotec). 
Purity was greater than 95% by flow cytometry. 2 × 105 purified CD8 T cells from a 
Pmel or OT1 mouse were co-cultured with pulsed splenocytes. Forty-eight hours after co-
culture, IFNγ was quantified in the tissue culture supernatant using a flow cytometric 
bead array according to the manufacturer's protocol (BD Biosciences).  
Splenic dendritic cell cross presentation 
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 For measurement of presented chicken ovalbumin (OVA) peptide, BL/6 mouse 
splenocytes were plated at a concentration of 4 × 105 cells/well in a 96-well plate in 
complete RPMI 1640 media. Splenocytes were pulsed with 10 µg indicated tumor lysate 
with or without 10 µg peptide containing the core OVA-derived SIINFEKL/ H-2Kb 
epitope (EVSQLEQLESIINFEKLTEEWTSSNVM) and incubated for 24 hours. Cells 
were harvested, stained for CD11c, MHC II, and SIINFEKL-H-2Kb, and analyzed by 
flow cytometry as described below. 
Western immunoblot 
 GL261 murine glioma cells were washed, pelleted, and lysed in radio-
immunoprecipitation assay buffer containing protease and phosphatase inhibitors 
(Pierce).  Protein concentration was determined, and 40 µg were loaded per lane and 
separated on a 4% to 12% SDS-PAGE gel. Gels were transferred to nitrocellulose, 
blocked, and incubated in 1:1000 anti-human HSP60 (cross-reacts with mouse, 
polyclonal, Santa Cruz Biotechnology), 1:1000 anti-human HSP70 (cross-reacts with 
mouse, clone N27F34, Abcam), , anti-human HSP27 (G3.1, Santa Cruz Biotechnology), 
and anti-mouse b-actin (Abcam) in blocking buffer for 1 hour. Membranes were then 
washed six times before incubation in 1:20,000 anti-goat, mouse, or rabbit IgG HRP 
(Jackson ImmunoResearch) in blocking buffer for 1 hour.  Nitrocellulose was incubated 
in ECL Plus chemiluminescent substrate (GE) for 5 minutes, drained, and exposed to 
HyBlot CL Autoradiography film (Denville Scientific) for 30 seconds.   
Flow Cytometry 
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 Analyses of stained dendritic and CD8 T cell suspensions were performed on a 
custom Canto II(BD) and analyzed with FlowJo software (Tree Star, Inc.). 
Fluorochrome-conjugated mAbs used were CD11c—FITC (eBioscience, clone N418), 
SIINFEKL-H-2Kb—PE (eBioscience, clone 25-D1.16), and I-A/I-E—eFluor450 (MHC 
II; eBioscience, clone M5/114.15.2).  The corresponding isotype controls were also 
purchased from eBioscience.   
Glioma Model 
C57B/6J mice were purchased from Jackson Laboratories and maintained in specific 
pathogen-free facilities at research animal resources at the University of Minnesota. The 
murine GL261 glioma model was established as described previously (133, 145). Briefly, 
15,000 luciferase-expressing GL261 cells in 1µL PBS were stereotactically injected into 
C57BL/6J female mice (6-8 weeks of age).  The site of implantation was the right 
striatum, 2.5 mm lateral, 0.5 mm anterior to bregma and 3.0 mm deep from the cortical 
surface of the brain.   
Immunization Protocol 
GL261 cells were dissociated with non-enzymatic cell dissociation buffer (Sigma), 
washed three times in PBS, resuspended in 500 µL PBS, and frozen initially by placing in 
−80°C overnight.  Cells were further lysed by five cycles of freezing in liquid nitrogen 
and thawing in a 56°C water bath. The protein concentration of the supernatant was 
determined using a Bradford assay.  Pellets were resuspended, and lysates were stored at 
−80°C until use for vaccination or in vitro experiments.  Each tumor-bearing mouse was 
vaccinated with 65 µg protein lysate mixed with phosphorothioated type-B CpG ODN 
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685 (5′-tcgtcgacgtcgttcgttctc-3′; SBI Biotech; Tokyo, Japan) in a final volume of 100 µL 
injected intradermally.  Vaccine was injected (50 µL) in the lower neck and (50 µL) in 
the left inguinal region.  
RESULTS 
Lysates from atmospheric oxygen are immune-suppressive  
 In effort to understand the changes that enable increased efficacy of lysate 
vaccines from physiologic oxygen, we focused on the outcome of cross priming.  In vitro 
experiments of cross priming demonstrate that decreasing O2 levels by four-fold leads to 
increased dendritic cell cross presentation and increased IFNγ production by CD8 T cells 
(135).  These medium-throughput assays were used to further investigate properties of 
lysates from 5% and 20% O2.  First was the finding that lysates from 20% O2 suppress 
cross presentation and cross priming compared to treatment with antigen alone, strongly 
suggestive of the presence of immune suppressive molecules (Fig. 2.1 A&B).  However, 
it was unknown what mechanism(s) of suppression occurred.   
Pharmacologic hypoxia reverses immune suppression 
 Cells possess many mechanisms to adjust to changes in oxygenation in their 
environments.  The most well known mediators of altered gene expression from lowered 
O2 are hypoxia-inducible factors (HIFs).  GL261 cells, like almost all cells, upregulate 
HIF 1α and 2α below 6% O2 (137).  We added desferrioxamine (DFX) to GL261 cultures 
in atmospheric O2 as a method to mimic low O2 culture, as it is known to increase the 
expression of HIF 1α and 2α in many cell types, including gliomas (129).  Lysates from 
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cells treated with DFX in 20% O2 were better able to induce cross priming compared to 
untreated cells, implicating HIFs in the immunogenic response (Fig 2.2).  
Cross presentation is maximally increased at 2% O2 
 Culture of glioma cells in 5% O2 in previous studies was chosen for practical 
reasons: due to ease of proliferation and the ability to maintain large incubators at this 
tension for large-scale culture.  Oxygenation levels in gliomas range from 0.1 to 8% O2 
(136), and it is unknown which levels are most immunogenic.  GL261 cells were cultured 
in 20%, 5%, 2%, and 1% O2, for at least two weeks, harvested for lysate production, and 
lysates were co-delivered with an ovalbumin peptide fragment to splenic dendritic cells to 
assess cross presentation.  Surface levels of peptide—MHC I complex were greatest in 
cells pulsed with lysate from 2% O2, suggesting efficacy of vaccines could be further 
improved (Fig. 2.3).  Moreover, lysates from 1% O2 were about as effective as those from 
5% O2, suggesting a peak of immunogenicity is present within the physiologic O2 range 
(Fig. 2.3).   
Decrease to 1% O2 causes increases in heat shock proteins 27 and 70 
 Many molecular changes could underlie the differential responses seen in lysates 
from 20, 5, 2, and 1% O2.  These lysates were probed for several stress-related proteins 
that have been implicated in immune responses.  We observed expression changes 
through titration of O2 (Fig. 2.7).  While heat shock protein 60 showed appearance of a 
doublet in 5% and 2% O2, its levels did not change appreciably across O2 levels.  In 
contrast, heat shock proteins 27 and 70 dramatically switched on expression following 
culture in 1% O2 (Fig. 2.4). 
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Vaccines from 2% O2 fail to extend survival in murine glioma  
 The immunogenicity of lysates from 2% O2 was tested by vaccination of GL261-
bearing mice with these lysates in combination with CpG 685 ODN, the adjuvant used in 
previous studies (135).  Interestingly, these vaccines failed to extend survival; however, 
efficacy of 5% O2 lysate vaccines in this study failed to reach statistical significance 
(p=0.11; Fig 2.5). 
DISCUSSION 
 These studies are a starting point for optimizing of glioma cultures for increased 
cross priming.  While lysates from 5% O2 act in an adjuvant manner to increase cross 
presentation and cross priming, those from 20% O2 act suppressively.  Many immune-
suppressive molecules have been described in glioma cells and could be responsible for 
suppression in 20% O2.  Several examples are: (1) TGFβ, one isoform of which was 
originally discovered in gliomas (146).  Interestingly, membrane expression of latent 
associated peptide (LAP) of TGFβ1 was greater in primary human glioma cells cultured 
in 5% O2 than those in 20% O2, decreasing the likelihood of its role here (133); (2) 
butyrophilin 1A1, which was overexpressed in 20% O2-cultured primary human gliomas 
as measured in Illumina microarray (133), and is known to suppress T cell responses 
(147).  Attempts at western blotting BTN1A1 in GL261 were unsuccessful due to lack of 
antibody reactivity (data not shown); (3) CD200, the expression of which is upregulated 
in primary human glioma cultures from 20% O2 (133).  Recent studies also demonstrate 
that antagonizing the CD200 axis in GL261 vaccines improves cross priming and 
survival (data not shown).  Numerous other mechanisms or combinations of mechanisms 
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could contribute to immune suppression.  A logical next experiment for determining the 
role of each molecule or mechanism would be to test the immunogenicity in GL261 cells 
with a loss of function in the suspected molecules (in 20% O2), and/or in dendritic or 
CD8 T cells with losses of function in the receptors or suppressive pathways involved.   
 Non-protein molecules cannot be ruled out when considering mechanisms of 
immune stimulation or suppression.  Immune-stimulatory or -suppressive lipids or 
carbohydrates have variable half-lives, and their production kinetics are less well 
understood (148).  Investigation of these molecules in loss of function experiments is 
more difficult as genetic ablation is often not able to result in precise loss of one 
molecule.  Neutralizing antibody experiments may prove more fruitful in the future if 
non-protein candidates are identified in screens.  
 Evidence for HIF-regulated control of immunogenicity is suggested by the 
increase in cross priming of glioma cells from atmospheric oxygen, treated with the iron-
chelator, desferrioxamine (DFX).  DFX binds to Fe(II) within prolyl hydroxylase 
enzymes, inhibiting their ability to hydroxylate HIF α subunits for degradation (144, 
149).  Additional studies in with HIF1α or HIF2α loss function in GL261 cells would be 
necessary to demonstrate the requirement for HIFs in immunogenicity. 
 By repeating previous cross presentation studies with additional lysates from 2% 
and 1% O2 we observed that immunogenicity varies enormously as glioma cultures 
decrease O2 by small increments.  Importantly, cells were cultured for a two-week period, 
and all cultures continued to show cell division during this time.  While lysates from 2% 
O2 doubled the efficiency of cross presentation, those from 1% O2 were equally effective 
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at cross presentation as those from 5% O2.  However, lysate vaccines from 2% oxygen 
failed to extend survival as those from 5% oxygen in one survival study.  This survival 
study must be repeated for definitive conclusions to be made, as the sample size is small 
and mice treated with lysate from 5% O2 within the same group did not benefit from 
vaccination as much as in previous studies.  Loss of immunogenicity one gained may be 
due to HSP27 or 70 upregulation, but many other mechanisms are also possible.  
 This study describes the highly dynamic immunogenicity of glioma cells across a 
a broader O2 range.  Analysis of the differential gene expression in lysates from different 
O2 tensions may enable identification of important immunogenic players, known or 
unknown, for improvement of glioma lysate vaccines.  We chose to focus on lysates from 
5% O2 due to their consistent efficacy in vaccines (135).  Further studies sought to assess 
mechanisms related to feasibility, safety, and mechanisms of immunogenicity in a large 
animal model of another brain tumor, meningioma, and to characterize one molecule’s 
contribution to adjuvant immunogenicity in 5% O2 culture.   
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FIGURES 
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Figure 2.1: Suppression of cross presentation and cross priming by GL261 lysates 
from atmospheric oxygen.  A, splenocytes were pulsed with a peptide fragment of 
chicken ovalbumin containing SIINFEKL alone or in combination with lysate from 20% 
O2. Cross presentation in CD11c+ cells was measured 24 h later with a fluorochrome-
conjugate antibody recognizing SIINFEKL—H-2Kb. B, Splenocytes were pulsed with a 
peptide of the Pmel-1 CD8 T cell epitope alone or in combination with lysates from 20%  
O2, responder Pmel CD8 T cells were added and IFNγ was measured by bead array 48 h 
later. Error bars, SEM; Lines, p<0.05 by unpaired t-test. 
 
 
 
 
 
  36 
 
 
Figure 2.2: Enhancement of cross priming by GL261 lysates from atmospheric 
oxygen treated with a HIF-stabilizer, desferrioxamine (DFX).  Splenocytes were 
pulsed with a peptide of the Pmel-1 CD8 T cell epitope alone or in combination with 
lysates from 20% or 5% O2, responder Pmel CD8 T cells were added and IFNγ was 
measured by bead array 48 h later. Error bars are SEM; *, p<0.05 by unpaired t-test. 
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Figure 2.3: Increased numbers of peptide—MHC I complexes on dendritic cells 
pulsed with lysates from 5%, 2%, and 1% O2.  Splenocytes were pulsed with a peptide 
fragment of chicken ovalbumin containing SIINFEKL alone or in combination with 
GL261 lysate from 20%, 5%, 2%, or 1% O2. Cross presentation was measured 24 h later 
by labeling with a fluorochrome-conjugated antibody recognizing the SIINFEKL—H-
2Kb complex.  Cells were gated on the dendritic cell (CD11chiMHCIIhi) population.  Error 
bars are SEM, and lines show p<0.05.  
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Figure 2.4: Differential expression of stress-related proteins in GL261 cells cultured 
in four oxygen concentrations. GL261 cells were cultured in the indicated oxygen 
concentrations for at least two weeks, and aliquots were taken for vaccination and half of 
each aliquot was flash-frozen and blotted for the indicated proteins following SDS-
PAGE. 
 
 
 
 
Figure 2.5: Lysate vaccination from cells cultured in 2% O2 is ineffective.   
Kaplan-Meier plot of mice vaccinated with saline or GL261 lysate from the indicated O2 
tension and CpG 685 ODN (n=7 per group). p=0.11 by log-rank. 
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CHAPTER THREE 
 
VACCINATION FOR INVASIVE CANINE 
MENINGIOMA WITH AUTOLOGOUS LYSATE 
FROM PHYSIOLOGIC OXYGEN INDUCES IN SITU 
PRODUCTION OF ANTIBODIES CAPABLE OF 
ANTIBODY-DEPENDENT CELL-MEDIATED 
CYTOTOXICITY2 
 
 
SUMMARY 
 Malignant and atypical meningiomas are resistant to standard therapies and 
associated with poor prognosis.  Despite progress in the treatment of other tumors with 
therapeutic vaccines, this approach has not been tested preclinically or clinically in these 
tumors.  Spontaneous canine meningioma is a clinically meaningful but underutilized 
model for preclinical testing of novel strategies for aggressive human meningioma.  We 
treated 11 meningioma-bearing dogs with surgery and vaccine immunotherapy consisting 
                                                 
2 Adapted with permission from Brian M. Andersen, G. Elizabeth Pluhar, Charles E. 
Seiler, Michelle R. Goulart, Karen S. SantaCruz, Melissa M. Schutten, Joyce P. Meints, 
M. Gerard O’Sullivan, R. Timothy Bentley, Rebecca A. Packer, Stephanie A. 
Thomovsky, Annie V. Chen, Dominik Faissler, Wei Chen, Matthew A. Hunt, Michael R. 
Olin, and John R. Ohlfest. “Vaccination for Invasive Canine Meningioma Induces In Situ 
Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity” 
Reprinted from © 2013 The American Association for Cancer Research. Originally 
published in Cancer Research. 2013. 73:2987-2997. 
 
 
  40 
of autologous tumor cell lysate combined with toll-like receptor ligands.  We attempted 
to enhance immunogenicity by culturing autologous tumor cells for vaccination in 5% 
oxygen, which showed a trend for the best therapeutic benefit in murine glioma in 
Chapter Two and previous publications.  Therapy was well tolerated, and only one dog 
had tumor growth that required intervention, with a mean follow up of 585 days.  
Interferon gamma elaborating T cells were detected in the peripheral blood of two cases, 
but vaccine-induced tumor-reactive antibody responses developed in all dogs.  Antibody 
responses were polyclonal, recognizing both intracellular and cell surface antigens, and 
heat shock protein 60 was identified as one common antigen.  Tumor-reactive antibodies 
bound allogeneic canine and human meningiomas, demonstrating common antigens 
across breed and species.  Histological analysis revealed robust infiltration of antibody-
secreting plasma cells into the brain around the tumor in post-treatment compared to pre-
treatment samples.  Tumor-reactive antibodies were capable of inducing antibody 
dependent cell-mediated cytotoxicity to autologous and allogeneic tumor cells.  These 
data demonstrate the feasibility and immunologic efficacy of 5% O2-derived vaccine 
immunotherapy for a large animal model of human meningioma and warrant further 
development towards human trials. 
INTRODUCTION 
Meningioma is the most common primary brain neoplasm, with over 100,000 
patients diagnosed in the United States between 2004 and 2008 (17).  Newly diagnosed 
tumors are managed by surgical resection alone.  Roughly 6,000 patients will need 
additional treatment in the United States every year due to recurrence (9), which often 
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occurs with invasive or malignant disease (150, 151).  Current salvage approaches 
include re-operation, radiation, radiosurgery and chemotherapy; there is controversy 
regarding the perceived clinical benefit of these interventions (12, 152-154).  The three-
year recurrence rate in re-operated World Health Organization (WHO) grade I 
meningioma is 50% (155), with risk of recurrence even greater in grade II and III tumors 
(8, 13, 156).  Radiation, while modestly effective in benign disease, has been associated 
with cognitive deficits, secondary malignancies, and the transformation of the tumor to a 
higher-grade neoplasm (9).    
One challenge in treating aggressive meningiomas is the paucity of animal models 
with which to test combinations of surgery and systemic therapy in a meaningful manner.  
Spontaneous meningiomas in dogs make up 45% of primary canine brain tumors (157) 
and are an under-utilized resource for preclinical studies.  Canine and human 
meningiomas share many features, including histological resemblance, overexpression of 
growth factor receptors, deletion of chromosomal segments, and losses of function in 
tumor suppressor genes (158-160).  Over 40% of canine meningiomas were atypical or 
malignant in one study (161).  Dogs develop many other cancers that are prevalent in 
humans, and tumors progress 5-7-fold faster in dogs relative to humans (162).  We 
hypothesized that preclinical studies in canine meningioma would enable accurate and 
rapid testing of immunotherapy for aggressive meningioma.   
Cancer vaccines have been tested in multiple malignancies, including gliomas, 
with evidence of clinical activity (45, 55).  A meta analysis covering over 100 clinical 
trials revealed that response rates to vaccination with peptides containing defined T cell 
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epitopes were less than half of that achieved with whole cell-based vaccines (40).  The 
higher response rate achieved with whole cell vaccines (as used in this study) could be 
due to greater antigenic coverage or the potential to induce tumor-binding antibodies.  
Meningiomas are not subject to the same principles of immune privilege as cells within 
the brain parenchyma such as gliomas (163).  Relative to gliomas, meningiomas may be 
better candidates for immunotherapy because they: (1) are not insulated by the 
endothelial tight junctions that limit large molecule (e.g. antibody) diffusion; (2) are in 
direct contact with cerebrospinal fluid that drains to the venous circulation and cervical 
lymph nodes for antigen presentation to T and B lymphocytes; (3) lack the T cell 
trafficking checkpoints present in the Virchow-Robin space (e.g., glia limitans); and (4) 
are relatively slow growing tumors that may be more susceptible to adaptive immune 
responses.  However, invasive, atypical, and malignant meningiomas can infiltrate the 
brain parenchyma, requiring penetration of antibodies and/or lymphocytes for control of 
post-surgical, microscopic disease. 
 Tumor cell lysates mixed with synthetic toll-like receptor (TLR) ligands function 
as effective vaccines to induce anti-tumor immune responses in glioma-bearing animals 
(164, 165).  The mechanisms of lysate/TLR ligand vaccines have been thoroughly 
characterized and tested in many cancer patients; however, the activity of this type of 
vaccine against meningioma is unknown.  TLR activation on antigen presenting cells 
facilitates the induction of adaptive immune responses by enhancing antigen presentation, 
expression of co-stimulatory molecules, cytokine production, and homing to secondary 
lymphoid organs.  The TLR 9 ligand CpG olidgodeoxynucleotide induced clinical 
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responses in select melanoma and renal cell carcinoma patients (166, 167). The FDA-
approved TLR 7 ligand imiquimod exhibited adjuvant activity in cancer clinical trials 
(45, 168), with excellent efficacy as a single topical agent against skin cancers (169).   
 We conducted a vaccine immunotherapy trial for pet dogs with symptomatic, 
spontaneous meningiomas. Dogs underwent surgery followed by vaccination with 
autologous tumor cell lysate from 5% O2 culture that was combined with imiquimod or 
CpG.  Herein we report safety, robust extension of survival, homology among antibody 
epitopes between dogs and humans, and vaccine-induced, local antibody production in 
the brain.  Vaccination for canine meningioma reveals promising avenues for further 
development towards human trials.   
METHODS 
Surgery, Vaccination Production, and Administration 
Dogs were enrolled after obtaining owner consent according to an approved 
protocol from the University of Minnesota IACUC. A presumptive diagnosis of 
meningioma was based on the MRI characteristics of a solitary extra-axial mass in the 
brain, with heterogeneous T1W signal, usually isointense, homogenous T2W signal, 
sharply defined borders, homogenous contrast enhancement, evidence of a dural tail, that 
may have associated cysts, peritumoral edema and falx-shift.  Surgical resection was 
performed under general anesthesia using the appropriate approach based on tumor 
location. Dogs were hospitalized with supportive care for 1-2 days after surgery.  
Corticosteroids used to minimize peritumoral edema were discontinued by 48 hours 
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before vaccination. Part of the tumor specimen was used for histological diagnosis, and 
the remainder of the tumor was cultured for vaccine production. 
Cultures were established by mincing specimens with scalpels and digestion at 37 
°C for 15 minutes in suspension with TrypLE Express (Invitrogen/Life Technologies). 
Cell suspensions were filtered through a 100 mm filter, washed with PBS, and placed in 
culture in 10 cm culture plates pre-coated with 1:10 Matrigel (BD Biosciences), in 
serum-free neural stem cell media consisting of DMEM:F12 (1:1), with L-glutamine, 
sodium bicarbonate, penicillin/streptomycin (100 U/mL), B27 and N2 supplements 
(Gibco), and 0.1-mg/mL Normocin (InVivoGen).  Semi-weekly, cells were given 20 
ng/mL rhEGF and rhFGF (R&D systems) and were cultured at 5% O2 and 5% CO2.  
Harvest for vaccination involved scraping cells from one 10 cm dish. Cells were washed 
thrice in PBS, and underwent five freeze-thaw alternations by transfer from warm water 
bath to liquid N2 followed by radiation (200 Gy). Protein was measured by Bradford 
assay with standard Coomassie reagent (Pierce), and lysates were stored at -80 °C.  
GMP-grade CpG 685 ODN was provided by SBI Biotech Co., Ltd  (Tokyo, Japan), and 
imiquimod cream was acquired through the University of Minnesota Boynton Health 
Services Pharmacy.  In five dogs, CpG (2.0 mg) was mixed with thawed lysates 
immediately before intradermal injection at two sites in the back of the neck. Six other 
dogs received imiquimod cream (5%; 0.5 g) at two intradermal injection sites in the back 
of the neck 15 minutes prior to lysate injection.  The maximally achievable lysate protein 
concentration was given to each dog, which varied by tumor volume and the ability of the 
tumor to proliferate in culture.  Lysate doses ranged from 200 to 1,500 µg protein 
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(average of 595 µg), and average dose did not vary significantly between CpG and 
imiquimod-treated dogs.   
Tumor Volume Measurements  
Twenty consecutive surgical human cases (of MAH) were analyzed for volume 
by MRI, as calculated by [Length x width x height]/ 2 for tumor and intracranial volume. 
The same procedure was carried out for the eleven dogs in this study and the results were 
compared as described in supplementary methods. 
Western Immunoblot 
Cultured tumor cells or homogenized flash-frozen tumors were used for blotting. 
Cells were lysed, protease and phosphatase inhibitors (Calbiochem, San Diego, CA) were 
added, and for SDS-PAGE, lysates were diluted in laemmli reducing sample buffer, 
heated, and centrifuged. Protein standards (BioRad, Hercules, CA) were loaded next to 
each 40 µg lysate and resolved on NuPAGE 4–12% Bis/Tris gels (Invitrogen). Proteins 
were transferred to nitrocellulose (Amersham) at 5 V constant voltage using semi-dry 
transfer (BioRad). The membranes were blocked in 5% NFDM/TTBS at room 
temperature for 1 hour and cut appropriately into identical blots, each with a molecular 
weight standard (Bio-Rad) run adjacent to lysate. Each membrane was incubated at room 
temperature for 1 hour in normal, pre- or post-vaccination sera diluted 1:1000 in 5% 
NFDM/TTBS, washed six times for 10 min each in TTBS, followed by room temperature 
for 1 hour in rabbit anti-canine IgG HRP-conjugated secondary antibody (Jackson 
ImmunoResearch) at 1:50,000 in 5% NFDM/TTBS. Bands were detected using ECL 
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Western Blotting Detection System (Amersham) and HyBlot CL autoradiography film 
(Denville Scientific). Densitometry was performed by the Gel Analysis tool in ImageJ 
1.45s software (NIH), and values were normalized by dividing by heavy and light chain 
densities (areas under the curve) from prevaccination lanes. 
Detection of Tumor Cell Surface-Reactive Antibodies 
A Becton Dickinson Custom Canto three-laser flow cytometer was used for data 
acquisition. Tumor cells were removed from Matrigel™-coated 10 cm culture plates by 
scraping or BD Dispase (BD Biosciences), washed with PBS thrice, and incubated with 
heat-inactivated normal dog, prevaccination, or 3-month post-vaccination serum at 1:100 
dilutions at 4° C for 30 minutes. Cells were then washed thrice in PBS and incubated 
with 1µg anti-canine IgG (H+L)—FITC (American Qualex) at 4° C for an additional 30 
minutes before washing and analyzing.  
Immunohistochemistry Staining and Quantification of Lymphocyte Infiltration 
For lymphocyte analysis, 5µm tissue sections were cut, prepared with standard 
procedures, and the following antibodies were used: CD3 (AbD Serotec) at 1:2000, CD20 
(Thermo Scientific) at 1:2000, and IgG (H+L; Jackson ImmunoResearch) at 1:2000.   
Tissue sections were incubated with the primary antibodies for 1 hour, rinsed, and a 
biotinylated secondary antibody was applied for 30 minutes.  CD20 and IgG antibodies 
were followed with undiluted Rabbit Link (Covance), and a biotin conjugated donkey 
anti-rat IgG (H+L) (Jackson ImmunoResearch) at 1:500 was used with CD3.  Sections 
were rinsed, incubated in hydrogen peroxidase, and a tertiary streptavidin horseradish 
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peroxidase link (Covance) for 30 minutes.  The immune complex was visualized using 
3,3′-diaminobenzidine as the chromogen.  Sections were lightly counterstained with 
hematoxylin, dehydrated, coverslipped, and scanned using the Aperio Scanscope XT. 
All surgical resection specimens and all necropsy blocks containing tumor or 
inflammation as seen by H&E staining were included in counting of CD3+ and CD20+ 
cells. Samples were blinded, and all 10X fields in slides were captured and saved as 
image files. Automated cell quantification was conducted with a customized macro and 
the particle analysis tool in Fiji software (ImageJ 1.46j, NIH). Counts underwent 
statistical analysis as described in supplemental methods before unblinding.  
Antibody-Dependent Cell-Mediated Cytotoxicity 
Dog blood from healthy donors was collected in anti-coagulant tubes, lysed 
osmotically, and peripheral blood leukocytes (PBLs) were washed thrice with PBS. PBLs 
were resuspended in complete RPMI 1640 (supplemented with 10% heat-inactivated 
FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 0.1 mg/mL Normocin from 
InVivoGen) in a 96-well plate at 2.5 x 106 cells/mL, and stimulated 14 hours with 30 µM 
of the TLR7/8 ligand resiquimod before being washed and co-cultured with antibody-
coated tumor cells.  Primary meningioma cultures were coated with antibody as described 
in the cell surface binding procedure.  Two washes were performed before addition to 
PBLs at an effector:target ratio of 25:1. Tumor cell lysis was determined by measurement 
of lactate dehydrogenase (LDH) activity as indicated by the manufacturer’s protocol after 
seven hours of co-culture (Roche Applied Science).  Percent specific lysis of tumor cells 
was calculated by: [Sample- (tumor only + PBL only)] / (lysed tumor + PBL only) x 100. 
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Statistical Analysis 
Samples were analyzed by unpaired t-test (tumor/brain volume, flow cytometry, 
LDH activity). Histological cell counts were analyzed by an unpaired t-test with Welch’s 
correction for unequal variances with 95% confidence intervals. Survival was analyzed 
using a logrank test with 95% confidence intervals. All statistics were conducted using 
GraphPad Prism version 4.0c for OS X (GraphPad Software, San Diego CA, 
www.graphpad.com). 
RESULTS 
Canine Meningiomas Model Aggressive Human Disease 
 Meningiomas from dogs treated in our study share histological features with 
human tumors of the same subtype (Fig. 3.1A), in addition to features that signify poor 
survival in humans.  Brain invasion is an independent negative prognostic factor that 
prompted the reclassification of otherwise WHO grade I meningiomas as grade II (7).  
Two canine cases exhibited gross tumor invasion into the brain at resection, and three 
additional cases showed brain invasion upon postmortem analysis (Fig. 3.1B, left, and 
Table 3.1).  Tumor invasion into the skull was also present in two cases (Fig. 3.1B, right).  
In addition, canine meningiomas occupied more than twice the volume of the brain 
relative to human tumors (Fig. 3.1C).  All dogs were symptomatic at the time of 
diagnosis, and in ten dogs, the presenting clinical sign was seizures.  The rapid recurrence 
and progression of this disease in canines is consistent with the common appearance of 
invasion into brain, which, in humans, predicts poor outcomes.   
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Extension of Survival Following Vaccine Immunotherapy  
Eleven dogs underwent craniotomy for tumor removal after radiographic 
diagnosis of an intracranial neoplasm consistent with meningioma.  Following 
histological confirmation, dogs were administered vaccinations biweekly with 
meningioma cell lysate from 5% oxygen culture in combination with CpG or imiquimod 
(Fig. 2A).  Mean follow-up time was 585 days, with 36% (4/11) of dogs alive (Table 3.1; 
Fig. 3.2 B&C).  Relative to historical controls, median survival is extended in the 
immunotherapy cohort (645 versus 222 days, p<0.05), with no censoring of dogs that 
died from other causes (Fig. 3.2B and Table 3.2).  Neither vaccination cohort contained a 
case of frank tumor progression, although more deaths occurred in the CpG cohort (Fig. 
3.2C).  One CpG-treated dog developed two meningiomas, of which the second was not 
identified before vaccination due to small size.  The second tumor was subsequently 
removed after its growth caused breakthrough seizures, and four other vaccines were 
given using tumor lysate of the second tumor.    
Tumor-Reactive Antibodies Bind Cell Surface Antigens and Cross-React with 
Human Meningiomas 
Immune responses before and after vaccination were measured in peripheral 
blood mononuclear cells (PBMCs) and sera.   Interferon gamma elaborating tumor-
reactive T cells were significantly increased in post-vaccination PBMCs in two of nine 
dogs tested, suggesting a low frequency of circulating T cells three months after surgery 
(Table 3.3).  In contrast, polyclonal tumor-reactive antibody responses to whole tumor 
lysate (Fig. 3.3A) and cell surface antigens (Fig 3.3B&C) were detected in all eleven 
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dogs (Table 3.3).  Probing of allogeneic tumor cells and lysates indicated recognition of 
common tumor antigens among dogs, some of which were present on the cell surface 
(Fig. 3.4A-C).  Post-vaccination antibodies recognized recombinant human HSP60 and 
HSP60 from autologous and allogeneic tumor (Fig. 3.4A), demonstrating the common 
expression and recognition of this antigen.  Remarkably, post-vaccination canine serum 
recognized human meningioma tissue, indicating antigen conservation between species 
(Fig. 3.4D).  
Vaccination Induces T, B and Plasma Cell Infiltration into Peritumoral Brain 
We conducted analyses of B and T cell infiltration in surgical and necropsy tissue 
in the four cases in which it was available.  Three CpG-treated dogs died within three 
weeks of the final vaccination and exhibited robust, focal increases in B (with relatively 
less T) cell infiltration into peritumoral brain (Figs. 3.5A&B; Cases 1, 3, and 5).  One 
imiquimod-treated dog developed acute lymphoblastic lymphoma and was euthanized 25 
weeks after the final vaccination. This dog showed mild B cell infiltration (and no T cell 
infiltration) into the brain (Fig. 3.5B; case 8).  As mentioned above, case 3 presented with 
a second meningioma in the contralateral hemisphere between the fifth and sixth 
vaccinations, which was subsequently resected.  Western analysis revealed a profound 
increase in IgG penetration into the second tumor relative to the first, pre-vaccination 
tumor (Fig. 3.5C&D).  Moreover, staining for canine IgG exposed plasma cells in the 
brains of three CpG-treated dogs (Fig. 3.5E).  While previous studies have reported 
plasma cell entry into the brain in antibody-mediated autoimmune (170) and anti-
pathogen (171) responses, this is the first account of induced plasma cell homing into 
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brain tumors.  In situ antibody production was further suggested by focal areas of 
extracellular IgG staining seen in plasma cell-containing areas of brain tissue but not 
others (data not shown).    
Recognition of Non-Neoplastic Brain and Meningeal Antigens by Post-vaccination 
Sera  
Two dogs (cases 3 and 5) were euthanized seven and twenty days after the most 
recent vaccination.  Both animals presented with uncontrollable seizures and tumor 
recurrence was assumed.  At necropsy, case 3 had a microscopic focus of residual tumor 
and case 5 had no evidence of tumor.  To evaluate vaccine-induced autoantibody 
production, sera from these and three other dogs was probed against normal dog brain, 
arachnoid/pia mater, and dura mater.  Secondary antibody revealed heavy and light chain 
IgG and IgM deposited in meninges, but not brain parenchyma (Fig. 3.6A, left). These 
results are consistent with the physiologic permeability of immunoglobulin into these 
tissues. Serum from cases 3 and 5 reacted to arachnoid/pia and brain parenchyma, 
respectively.  Consistent with the autoreactivity of case 5 sera, analysis of necropsy brain 
tissue from this dog revealed IgG accumulation on or in neurons distal to the site of 
resection (Fig. 3.6B).   The binding of the sera to normal brain antigens in these dogs sets 
them apart from two CpG treated dogs and one imiquimod treated dog that remained 
healthy and had non-reactive sera (Fig. 3.6A).  
Postvaccination Sera are Capable of Antibody Dependent Cell-Mediated 
Cytotoxicity 
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Anti-tumor effector activities of antibodies encompass multiple mechanisms, 
including antibody-dependent cell-mediated cytotoxicity (ADCC).  Since antibodies 
reacted with cell surface antigens (Fig. 3.3B&C; Fig. 3.4 B&C; Fig 3.7 A&B), and 
antibody production in situ could enable opsonization of invasive meningioma cells 
behind an intact blood brain barrier, we tested whether tumor-reactive antibodies could 
trigger ADCC.  Peripheral blood leukocytes killed few tumor cells when co-cultured with 
meningioma cells, or when tumor cells were pre-incubated with pre-vaccination serum; 
however, ADCC occurred when tumor cells were incubated with post-vaccination serum 
(Fig. 3.7C).  Post-vaccination serum also triggered ADCC against allogeneic meningioma 
cells (Fig. 3.7D), demonstrating that allogeneic vaccination may be an effective strategy 
in canines with meningioma.   
DISCUSSION  
 As many as 57,000 dogs a year develop meningiomas in the US (157, 172), and 
these dogs are an under-utilized resource for preclinical study.  Because the prognosis for 
canine meningioma is dismal (173), both dogs and humans could benefit from these 
studies.  Our data show the canine model resembles many histological subtypes observed 
in humans and has features associated with poor prognosis in humans.  The large size of 
the canine brain allows for surgery as a component of therapy, enabling a more realistic 
clinical interpretation of systemic interventions.     
 The survival outcomes of this study call for further investigation into the 
predictive potential of the canine model, especially with regard to tumor and immune 
biology in the two species.  Different responses to vaccination may occur due to 
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differential antigen expression, TLR expression in leukocyte cell types, tumor growth 
kinetics, the relationship between histologic subtype, biological behavior and clinical 
outcome.  
 Addition of lysate/adjuvant vaccination to surgery resulted in favorable survival 
compared to historical controls, but a prospectively designed, randomized study is 
required to make firm conclusions on therapeutic efficacy.  Nonetheless, only case 3 
experienced tumor growth despite treatment.  The survival data may underestimate the 
benefit of vaccination because censoring was not used (Fig. 3.2B&C).  Two dogs 
included in the analysis died of other malignancies, and two dogs lacked postmortem 
analysis but were assumed to die of age-related causes (Table 3.1).  The three other 
deaths were due to euthanasia after dogs presented with uncontrollable seizures assumed 
to be caused by tumor recurrence.  Postmortem analysis in these CpG-treated dogs found 
minimal or no tumor burden, but immunoreactivity to normal brain structures may have 
been treatment related and contributed to the acute onset of neurologic symptoms (Fig. 
3.6A&B).  Similar seizure activity in glioma-bearing dogs in clinical trials at our 
institution has been controlled using additional anti-convulsants, corticosteroids or 
induction of general anesthesia (data not shown).  It is therefore possible that the seizures 
in meningioma-bearing dogs could have been controlled.  Whether CpG or imiquimod is 
more efficacious is still unresolved from the current study due to the small number of 
dogs and many non-tumor-related deaths.  Given the high level of tumor control and the 
superior safety profile of imiquimod, however, a prospective randomized trial to compare 
  54 
surgery alone and in combination with vaccines of tumor lysate and a novel TLR 7/8 
ligand was initiated.  
 Our study is a starting point for investigation of immunotherapy for meningioma.  
The data indicate that B cell activation and antibody production is the predominant 
mechanism of immunity induced by vaccination. Tumor-reactive antibodies were 
detected in the serum of all dogs regardless of lysate dose, demonstrating feasibility of 
autologous lysate/TLR vaccine production.  Antibodies exhibited considerable inter-case 
and –species cross reactivity (Fig. 3.4 A&D; Table 3.3).  B cell infiltration outnumbered 
T cell infiltration in postmortem brain tissue adjacent to the resection cavity (Fig. 3.5B).  
In contrast, only two dogs had increased tumor-reactive T cell responses as measured by 
interferon-gamma ELISpot (Table 3.3).  However, it is likely that reactive CD4 T cells 
were primed following vaccination because antibody responses often require CD4 T cell 
help.  Tumor-reactive T cells in the blood may not represent what occurs in the tumor 
draining lymph nodes or tumor site.  A limitation of our study was that ELISpot was 
carried out only in pre-vaccination and 3-month post-vaccine blood samples.  
Nevertheless, infiltrating CD3+ cells were observed in dogs that died within two weeks of 
the final vaccination (Fig. 3.5 A&B), suggesting some T cell activation.  Future studies 
will examine T cell responses in greater detail. 
 Tumor antigens in lysate vaccines could include over-expressed normal antigens, 
mutated (neo-) antigens, oncofetal antigens (expressed during development), or tumor-
specific carbohydrates, glycoproteins, or lipoproteins.  That two dogs with severe post-
vaccine seizure activity had auto-reactive sera to brain and meninges suggests that severe 
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autoreactivity is possible but infrequent (Fig. 3.6 A&B).  Lysates may be depleted of 
these autoantigens to yield greater tumor specificity and less risk.  Since most dogs had 
no autoreactivity or refractory seizures, risk of autoimmunity must be weighed against 
the threat to life posed by aggressive meningiomas.   
 Identification of meningioma antigens recognized by post-vaccination sera will 
enable the discovery of crucial epitopes for fully synthetic vaccine strategies in more 
widespread application.  We identified HSP60 as one antigen recognized by sera 
following vaccination.  HSP60 can translocate to the cell surface upon stress or malignant 
transformation (174), but it was not expressed on the tumor cell surface of case 3 (data 
not shown), arguing against cell surface protein as the functional target of this antibody.  
Sera that recognized HSP60 also reacted with a human meningioma, and reactivity was 
observed at 60 kDa; however, more study is needed to determine if HSP60 is a relevant 
target in human meningioma.   
 Antibody-mediated autoimmunity is well characterized, with autoimmune 
conditions in the CNS such as multiple sclerosis being re-evaluated in light of clinical 
benefit seen from B cell depleting therapies (175).  Brain tumor immunotherapy, once 
focused on T cell-dependent mechanisms, is similarly expanding its breadth of effector 
mechanisms.  Orthotopic mouse models of glioma indicate that survival benefit from 
immunotherapy is absent in B cell deficient, µMT tumor-bearing mice (176) and 
unpublished results).  The importance of B cells and antibodies in brain tumor immunity 
are relatively unstudied.  Our study documents for the first time the induction of plasma 
cells homing to brain tumors as a consequence of therapeutic intervention.  B cell and 
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plasma cell infiltration into the brain also indicates promise for immunotherapy to act 
against invasive cells that exist behind an intact blood brain barrier.  ADCC due to in situ 
antibody production in brain is a novel immune effector mechanism relevant to any brain 
tumor.  Our data suggest that vaccination can induce a “Trojan horse”-like infiltration of 
plasma cells that can in turn trigger ADCC, and thus create excitement for translation of 
this approach to human meningioma and other CNS cancers. 
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FIGURES
 
S: Spayed; N: Neutered; I: Intact 
*Surgery: brain invasion seen in surgical pathology; Necropsy: brain invasion seen in necropsy  
Antibody reactivity: 1 to autologous tumor by western blot; 2. to allogeneic tumor by western blot; 3. to 
autologous surface antigens by flow cytometry; and 4. to allogeneic surface antigens by flow cytometry.  
† Neurologic symptoms were thought to be due to recurrence; euthanasia was chosen, and at postmortem 
analysis, minimal or no tumor was present. 
 
Case 
Number Age/Sex Breed 
Histological 
Subtype 
at Biopsy 
Brain 
Invasion* 
Vaccine 
Adjuvant 
MRI  
Response 
AB 
Response 
Cause of 
Death 
1 7 /M.I. Boxer Papillary No CpG Stable 1,4 Abdominal Tumor 
2 10 /F.S. Laborador Mix Papillary n/a CpG Stable 1,3 Unknown (Age-Related) 
3 11 /F.S. Laborador Mix Meningothelial Necropsy CpG 
Second Tumor, 
Reoperation 
Stable 
1,2,3,4 
Euthanasia      
(seizure 
activity)† 
4 9 /F.S. Doberman Mix Psammomatous Necropsy CpG Stable 4 Euthanasia      (paresis)† 
5 7 /M.N. Golden Retriever Transitional No CpG Stable 1 
Euthanasia     
(seizure 
activity)† 
6 6 /F.S. Afghan Hound Transitional n/a Imiquimod Stable 1,3,4 Alive 
7 12 /F.S. Weimaraner Meningothelial Necropsy Imiquimod Stable 1,3 Lymphoma 
8 13 /M.N. Poodle Meningothelial Surgery Imiquimod Stable 1,3,4 Alive 
9 7 /M.N. Great Dane Psammomatous n/a Imiquimod Stable 1,3,4 Alive 
10 11 /F.S. Schnauzer Mix Transitional n/a Imiquimod Stable 1,4 Alive 
11 8 /M.N. Beagle Psammomatous Surgery Imiquimod Stable 1,4 Alive 
 
Table 3.1: Information on dogs receiving autologous lysate/adjuvant vaccination for 
meningioma. 
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Figure 3.1: Canine meningiomas model aggressive human disease. A, meningioma 
surgery specimens stained with H&E, left to right, from cases 3, 4, and 1. B, necropsy 
specimens from 2 dogs with tumors that, in humans, are categorized as WHO grade II on 
biopsy. C, tumor volume and brain volume of the 11 dogs treated with surgery plus 
immunotherapy and 20 consecutive intrainstitutional patients with human meningioma. 0, 
P < 0.05. 
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Figure 3.2: Biweekly tumor lysate/adjuvant vaccination schedule results in 
prolonged survival of spontaneous canine meningioma. A, study design and immune 
monitoring scheme. B, surgery controls were conducted at 4 institutions, and all cases 
were confirmed to be meningioma by histopathology. C, comparison of CpG with 
imiquimod treatment groups. 
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Case Number Survival (Days post-operation) Histological Subtype 
12 6 Transitional 
13 17 Anaplastic 
14 48 Transitional 
15 67 Transitional 
16 69* Fibrous 
17 178 Meningothelial 
18 222 Epitheliomatous 
19 252 Meningothelial 
20 262 Meningothelial 
21 386 Unspecified 
22 428 Transitional 
23 1855 Unspecified 
Cases were seen at the University of Minnesota, Tufts University, Purdue University, and Washington State 
University. *Denotes dog that is still alive. 
  
Table 3.2: Survival of canines with meningioma following surgery monotherapy. 
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Table 3.3: Immune monitoring summary for vaccinated dogs. 
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Figure 3.3: Vaccination induces antibody responses to meningioma surface antigens. 
A, Western immunoblot analysis of autologous tumor cells from culture (cases 10 and 3) 
or snap-frozen tumor specimen (case 5). Normal dog serum (ND) was used as a control. 
B, live autologous tumor cells were stained with serum from prevaccination or 
postvaccination (at 82 days). C, aggregate data of 3 dogs from B. 0, P < 0.05; 00, P < 
0.005. 
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Figure 3.4: Antibodies recognize allogeneic dog and human meningiomas. A, 
Western immunoblot analysis of tumor cells from 3 cases and recombinant human 
HSP60. B, representative histograms of cell surface binding of primary tumor cells from 
case 7. C, quantification of serum antibody surface binding to an allogeneic papillary 
(nonstudy dog— recognized by case 3) and a meningothelial meningioma (case 7—
recognized by cases 4, 6, 7, and 9). D, Western immunoblot analysis of a human 
meningioma probed with postvaccination serum from case 3. 0, P < 0.05; 00, P < 0.005. 
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Figure 3.5: Vaccination induces B- and plasma cell infiltrates in peritumoral brain. 
A, representative images from CD3 and CD20 immunohistochemistry of biopsies and 
necropsies from case 1. B, quantification of CD3 and CD20 stains from cases 1, 3, 5, and 
8. C, IgG blotted on case 3 primary tumor (prevaccination) and contralateral tumor 
(postvaccination). D, densitometry of heavy and light chain bands from C. E, 
immunohistochemical stain of canine IgG (H+L), indicating plasma cell infiltrates in 
normal brain areas of cases 3 and 5. *, P<0.005. 
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Figure 3.6: Reactivity with normal brain correlates with neurologic symptoms in 
CpG-treated dogs. A, brain, arachnoid/pia mater, and dura mater were probed with 
secondary anti-canine IgG (H+L) alone, with serum from an allogeneic healthy dog, or 
postvaccination sera from 5 cases. Arrows indicate reactivity in dogs with neurologic 
symptoms following vaccination. B, necropsy specimen from case 5 stained for canine 
IgG (H+L). 
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Figure 3.7: Postvaccination serum enables ADCC. A and B, case 3 postvaccination 
serum antibodies bound autologous tumor (A) and allogeneic tumor (B) of papillary 
histology from a nonstudy dog. Postvaccination serum also enabled killing of autologous 
(C) and allogeneic (D) tumors when combined with allogeneic PBL. *, P < 0.05; **, P < 
0.005. 
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CHAPTER FOUR 
ANNEXIN II IS AN OXYGEN-REGULATED 
DAMAGE-ASSOCIATED MOLECULAR PATTERN  
 
Brian M. Andersen, Charles E. Seiler, Xia Junzhe, Peisheng Hu, Alan L. Epstein, Wei 
Chen, Bruce R. Blazar, Christopher A. Pennell, John R. Ohlfest, and Michael R. Olin. 
 
 
 
 
SUMMARY 
 
 Previously, we reported that culturing glioma cells at physiologic (5%) oxygen 
increases their immunogenicity when used as therapeutic vaccines.  However, the 
underlying mechanism(s) behind the enhanced immunogenicity were unknown.  Here we 
demonstrate that annexin II (ANXA2) is upregulated in glioma cells cultured at 5% 
oxygen.  Knocking down ANXA2 completely eliminated the therapeutic activity of 
vaccines from 5% oxygen cultured cells, while adding monomeric ANXA2 (ANXA2m) 
enhanced the efficacy of vaccines derived from glioma cells cultured in atmospheric 
(20%) oxygen.  This activity is Toll-like receptor 2-mediated. Moreover, a fragment of 
the N-terminus of ANXA2 is sufficient for TLR2 activity and can be fused to antigens in 
single-agent vaccines.  These data indicate that ANXA2m is a vaccine adjuvant and a 
potential danger signal within the body.  
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INTRODUCTION 
 
 Dendritic cells (DCs) are the leukocytes most adept at cross priming CD8 T cells 
by presenting exogenous antigens (49). In a process called cross presentation, DCs 
internalize exogenous proteins and degrade them into peptides that are routed to various 
compartments, where they may bind to nascent MHC class I molecules. Stable 
peptide/MHC I complexes are then delivered to the cell surface for presentation to CD8+ 
T cells. From this basic understanding, many approaches have been devised to direct 
tumor cell components to DCs to stimulate tumoricidal CD8 T cells in cancer patients 
(177). 
 Whether DCs are targeted directly within patients or are matured ex vivo (85, 
178), three signals are required for maximal cross priming: i) sustained cross 
presentation, ii) upregulation of co-stimulatory molecules on the DC membrane, and iii) 
cytokine release (179, 180).  Signaling initiated by ligation of pattern recognition 
receptors (PRRs), which detect conserved molecules from damaged cells or pathogens, 
initiates DC maturation and the enhancement of these three cross priming signals (86, 
181).  Pathogen-associated molecular patterns (PAMPs) such as nucleic acids (91), cell 
wall components (86, 182), and bacterial motility proteins (183) are PRR ligands that 
have been widely tested as tumor cell vaccine adjuvants (184).      
 Other adjuvant molecules that induce DC maturation through PRRs are the 
damage-associated molecular patterns (DAMPs), released from injured self-cells (185, 
186).  Understanding the cellular mechanisms of injury and the specific DAMPs released 
by injured tumor cells in tissue culture has led to several methods to increase the 
  72 
immunogenicity of tumor cell vaccines.  DAMPs from tumor cells are released or 
exposed by irradiation (187), anthracyclines (188), cardiac glycosides (189), platinum 
agents (187), or the combination of proteasome and lysosome inhibitors (190).  DAMPs 
that improve anti-tumor CD8 T cell responses include calreticulin (191), high mobility 
group box protein 1 (187), adenosine triphosphate (192), and filamentous actin (193, 
194).  Maximizing the release of DAMPs and preventing their degradation during cell 
death are popular strategies of enhance the adjuvant properties of tumor cell vaccines.  
Armed with increased quantities of DAMPs, in addition to a broad array of antigens, new 
incarnations of DC based tumor cell vaccines bring hope for increasing vaccine efficacy 
in the clinic.  
We have shown that decreasing tissue culture oxygen to physiologic levels (5%) 
leads to enhanced adjuvant activity of glioma cells in therapeutic vaccines (135). Here we 
demonstrate that DAMP upregulation is the predominant mechanism of increased 
immunogenicity from tumor cells cultured in physiologic O2.  Host expression of Toll-
like Receptor 2 (TLR2), a PRR that recognizes several DAMPs, was required for the 
efficacy of vaccines made from 5% O2 glioma lysates.  A subtractive proteomic screen of 
TLR2-binding partners in glioma cell lysates identified annexin II (ANXA2), a 36 kD 
calcium- and phospholipid-binding protein expressed in most cell types (145).  We 
characterize for the first time the role of monomeric ANXA2 as a DAMP capable of 
extending survival of tumor-bearing animals.  Intriguingly, the TLR2-active domain of 
ANXA2 is just fifteen amino acids in length, enabling synthesis of an antigen fusion 
peptide for use as a single-agent vaccine.  
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METHODS 
Animal models 
BALB/cJ, C57B/6J (BL/6) and Tlr2-B6.129-Tlr2tm1Kir/J (Tlr2-/-) mice were 
purchased from Jackson Laboratories and maintained in specific pathogen-free facilities 
at the research animal resources at the University of Minnesota. The murine GL261 
glioma model was established as described previously (135).  Briefly, 15,000 luciferase-
expressing GL261 cells in 1 µL PBS were stereotactically injected into C57BL/6J female 
mice (6-8 weeks of age).  The site of implantation was the right striatum, 2.5 mm lateral, 
0.5 mm anterior to bregma and 3.0 mm deep from the cortical surface of the brain.  The 
murine EMT6 mammary carcinoma was established by injection of 106 cells in 50 µL 
PBS into the rostral-most left mammary fat pad of 6-8 week-old BALB/cJ mice (135).  
The NS0 murine plasmacytoma model was established by injection of 106 “empty vector” 
cells (described below) in 100 µL PBS, intraperitoneally into 6-8 week-old female 
BALB/cJ mice (195). 
Cell culture 
GL261 cells for vaccination were cultured in media containing DMEM/F12 (1:1) 
with L-glutamine, sodium bicarbonate, penicillin/streptomycin (100 U/mL), B27 and N2 
supplements, and 0.1 mg/mL Normocin (InvivoGen).  GL261 cells were supplemented 
with rhEGF and rhFGF (20 ng/mL; Peprotech) semiweekly.  EMT6 cells, splenocytes, 
and T cells were cultured in RPMI 1640.  GL261 cells for inoculation were cultured in 
DMEM; both DMEM and RPMI media contained 10% fetal bovine serum, 
penicillin/streptomycin (100 U/mL), and 0.1 mg/mL Normocin. Two NS0 transfectoma 
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cell lines were established by transfection with a vector containing glutamine synthetase 
with or without a sequence of N-terminal His-tagged human ANXA2 (“ANXA2-
transfected” and “empty vector”).  NS0 cells were cultured in hybridoma medium 
without glutamine, with 10% dialyzed fetal bovine serum, glutamine synthetase 
supplement (Millipore), penicillin/streptomycin (100 U/mL), and 0.1 mg/mL Normocin.  
Immunization protocol 
Tumor cells were harvested with non-enzymatic cell dissociation buffer (Sigma), 
washed three times in PBS, resuspended in 500 µL PBS, and frozen initially by placing in 
−80°C overnight.  Cells were further lysed by five cycles of freezing in liquid nitrogen 
and thawing in a 56°C water bath. The protein concentration of the supernatant was 
determined by Bradford assay.  Pellets were resuspended, and lysates were stored at 
−80°C until use.  Each tumor-bearing mouse was vaccinated with 65 µg protein lysate 
mixed with or without 50 µg phosphorothioated type-B CpG ODN 685 (5′-
tcgtcgacgtcgttcgttctc-3′; SBI Biotech; Tokyo, Japan) or 1.5 µg recombinant human 
ANXA2 (AbD Serotec) in a final volume of 100 µL injected intradermally.  Vaccine was 
injected (50 µL) in the lower neck and (50 µL) in the left inguinal region for GL261-
bearing mice, and (50 µL) in each inguinal region for EMT6-bearing mice.  Vaccination 
for GL261 and EMT6-bearing mice was administered weekly starting three days after 
tumor implantation, for a total of six doses.  NS0-bearing mice received 65 µg lysate in 
100 µL PBS, with 50 µL in each inguinal region.  The NS0 “priming phase” consisted of 
vaccination four days in a row, starting three days after tumor implantation.  Then, NS0 
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study mice were given weekly “boost” doses starting ten days after tumor implantation, 
for a total of six boosts.  
Immunohistochemistry 
 Staining of GL261 tumor specimens from mice was done as previously described. 
Briefly, Mice were perfused, and standard processing, embedding, and re-hydration 
methods were employed.  Following rehydration, sections are put into ReVeal, 6.0 pH 
citrate buffer (Biocare Medical) and placed in a steamer followed by a cool-down. Slides 
were rinsed in tap water and placed into a PBS bath. Sections were blocked and then 
incubated at 4°C overnight with the primary antibody cleaved caspase 3 (Biocare 
Medical) at 1:400 dilution.  Twenty-four hours later, a biotinylated rabbit link (Covance) 
was applied for 30 minutes at room temperature followed by a tap water rinse and PBS 
bath. This was followed with a 4+ streptavidin AP label (Biocare Medical) at room 
temperature and rinsing with PBS. Vulcan Fast Red (Biocare Medical) was applied at 
room temperature.  The samples were counterstained with Harris hematoxylin, 
decolorized, rinsed in tap water followed by routine dehydration, and cover slipped using 
permount. Cleaved caspase 3+ cell number was quantified manually by a blinded review 
of histologic sections.  All tumors were harvested from mice that were sacrificed when 
moribund (five sections per animal, three animals per treatment group). 
Immunoblot  
GL261 and human glioma patient cells were washed, pelleted, and lysed in 
radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors 
(Pierce).  Protein concentration was determined, lysates were diluted in reducing sample 
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buffer and run on 4-12% SDS-PAGE.  Gels were then transferred to nitrocellulose, 
blocked, and incubated in 1:2000 anti-human ANXA2 (BD biosciences) in blocking 
buffer.  Blots were then washed and incubated in 1:20,000 anti-mouse IgG HRP (Jackson 
ImmunoResearch).  After additional washing, nitrocellulose was then incubated in ECL 
Plus chemiluminescent substrate (GE), drained, and exposed to HyBlot CL 
Autoradiography film (Denville Scientific).   
Immunoprecipitation  
Cold GL261 lysate was adjusted to a concentration of 2 mg/mL. 10 µL antibody 
was added to 500µL lysate followed by overnight incubation at 4°C with rocking.  40 µL 
Protein A/G Agarose (SantaCruz) was added and incubated at 4°C with rocking.  Beads 
were then washed, putting the final pellet in 80 µL Laemmli reducing sample buffer. Gels 
were run and blotted using the same antibodies as for precipitation: anti-mouse TLR2 
(Clone T2.5, SantaCruz), anti-mouse ANXA2 (Clone 5 BD Biosciences), and anti-mouse 
IgG HRP (Jackson ImmunoResearch).   
Bone marrow-derived dendritic cells and TLR activity 
For dendritic cell maturation experiments, bone marrow-derived dendritic cells 
(BMDCs) were made using a protocol modified from that of Inaba et al (196). Briefly, 
femurs and tibias were removed and flushed with saline.  Erythrocytes were lysed, and 
remaining leukocytes were washed and placed in 10 cm dishes at 2 x 106 cells/10 mL in 
complete RPMI 1640 and 20 ng/mL GM-CSF (Peprotech).  Non-adherent cells were 
removed and media was replaced every three days.  Six days post-bone marrow harvest, 
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loosely adherent cells were washed and placed at 100,000 cells per well in 200 µL 
RPMI/GM-CSF, in loosely capped polystyrene FACS tubes.   
HEK293 Blue cells stably express an AP-1 and NF-kB inducible secreted alkaline 
phosphatase gene and hTLR2 or hTLR7 (InvivoGen).  HEK293 and BMDC were 
stimulated with 50 ng/mL Pam3CSK4 (Imgenex), 2.5 µg/mL ANXA2 monomer 
(ANXA2m; AbD Serotec and Aviva Systems Biology), 6.5 µg/mL purified bovine 
ANXA2 heterotetramer (ANXA2t; Meridian), 5 µg/mL imiquimod (kindly provided by 
Dr David Ferguson, University of Minnesota), 2.6 µg/mL annexin V (AbD Serotec), or 
200 µg/mL ANXA2-OVA peptides, and control peptides were equimolar to ANXA2-
OVA.  Forty-eight hours following stimulation, BMDCs were stained and analyzed by 
flow cytometry, and HEK293 Blue supernatant was assayed for secreted alkaline 
phosphatase activity using QuantiBlue (normalized to media-only treatment; InvivoGen).  
Cross priming and cross presentation 
C57BL/6J and Tlr2-/- splenocytes were plated at a concentration of 2 × 105 
cells/well in a 96-well plate in complete RPMI 1640 media.  Splenocytes were pulsed 
with combinations of the following: 10 µg tumor lysate, 2.5 µg/mL ANXA2m (AbD 
Serotec), or 50 µg/mL human (h) gp10025-33 peptide (KVPRNQDWL) or the core OVA-
derived SIINFEKL/ H-2Kb epitope (EVSQLEQLESIINFEKLTEEWTSSNVM).  For 
measurement of presented chicken ovalbumin (OVA) peptide, splenocytes were 
harvested, stained for CD11c, MHCII, and SIINFEKL-H-2Kb, and analyzed by flow 
cytometry as described below.  For measurement of IFNγ, after 24h, Pmel CD8+ T 
lymphocytes, that express a Vα1/Vβ13 transgenic T cell receptor specific for a H-2Db-
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restricted epitope corresponding to amino acid positions 25-33 of gp100, were purified 
from spleen (197) (Miltenyi Biotec), and 2 × 105 per well were co-cultured with original 
splenocytes. Forty-eight hours after co-culture, IFNγ was quantified in media using a 
flow cytometric bead array (BD Biosciences).   
Cross priming was tested in vivo through sequential daily vaccination as described 
previously (198).  Briefly, non-tumor-bearing mice were vaccinated four days in a row 
with 100 µg chicken ovalbumin protein alone or in combination with the following: (1) 
1.5 µg ANXA2m (AbD Serotec), (2) 50 µg CpG 685 ODN (SBI Biotech; Tokyo, Japan), 
(3) 65 µg GL261 lysate (control or shANXA2(199)); or (4) with 50 µg peptides, with 
equimolar amounts of control peptides.  Mice were boosted three days following the 
fourth vaccine, and bled the following day for analysis.   
Flow cytometry 
Analyses of labeled cell suspensions were performed on a custom Canto II (BD) 
and analyzed with FlowJo software (Tree Star, Inc.).  Fluorochrome-conjugated mAbs 
used were CD11c—FITC (eBioscience, clone N418), CD86—PE (eBioscience, clone 
GL1), SIINFEKL-H-2Kb—PE (eBioscience, clone 25-D1.16) CD80—APC (eBioscience, 
clone 16-10A1), CD8a—APC (eBioscience, clone 53-6.7) and I-A/I-E—eFluor450 
(MHC II; eBioscience, clone M5/114.15.2).  The corresponding isotype controls were 
also purchased from eBioscience.  A PE—dextran-conjugated multimer of SIINFEKL—
H-2Kb was purchased from Immudex (Copenhagen, Denmark).    
CMV antigen-specific CD8 T cell activation by human monocyte-derived dendritic 
cells 
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5 x 105 HLA-A2+ immature DCs were pulsed with 2.5 µg/mL ANXANXA2m, 
with or without addition of 10 µg/mL of pp65495–503 (NLVPMVATV) and matured as 
described previously(133, 196).  Following maturation, DCs were washed 3 times, and 5 
x105 PBMCs from cytomegalovirus (CMV) sera-positive donors were added to DCs.  
CMV sera-negative PBMCs were used as a control. Cells were incubated for 48 hours, 
and supernatant was analyzed for IFNγ by cytometric bead array (BD Biosciences).  
Peptide synthesis 
A 15 N terminal ANXA2 peptide, a 36 amino acid N terminal-ovalbumin peptide 
fusion (“ANXA2-OVA”; STVHEILCKLSLEGDHSTPPSAYGSVKPYTNFDAE), 
S100A10-binding domain-truncated form of ANXA2-OVA (ANXA2-OVA-p11; 
DHSTPPSAYGSVKPYTNFDAEEQLESIINFEKLTEWT), and scrambled ANXA2-
OVA (GSCTESIEALHVLELVSPYTKSHNTPDSKGDYPFAEQLESIINFEKLTEWT) 
were synthesized (Genscript and New England Peptide), and confirmed by sequencing.  
Subtractive proteomics 
TLR2 binding molecules enriched in 5% O2 GL261 lysates were identified 
through precipitation with a in 5% O2 and 20% O2 GL261 lysates. Following 
precipitation, proteins were separated by molecular weight with SDS-PAGE, and protein 
bands were visualized by silver stain.  Immunoprecipitation.  GL261 tumor cells cultured 
in 5% or 20% O2 were washed, pelleted, and lysed in cold RIPA buffer containing 
protease and phosphatase inhibitors (Pierce).  Protein concentration was determined using 
BCA colorimetric method (Pierce).  Cold GL261 lysate concentration was adjusted to 
2mg/ml with 500 µL transferred to microfuge tube.  10 µL TLR2 homodimer—Fc 
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chimeric protein (R&D Systems) was added to lysate followed by overnight incubation at 
40C with rocking.  40 µL Protein A/G Agarose (SantaCruz) was added to lysate and 
incubated 4 hours at 40C with rocking.  Beads were then washed 8 times in cold TBS 
putting final pellet in 80ul Laemmli reducing sample buffer.  Sample were heated at 950C 
for 5 minutes, centrifuged at 16.1 x g for 1 minute and supernatant was run on 4 – 12% 
gel. Gel was stained with silver (BioRad) and slices of acrylamide were excised from gel 
based upon Western and Coomassie staining results.  Dry pieces of excised acrylamide 
treated with Acetonitrile/Water, dried, digested into peptides, extracted and run on LC-
MS/MS for protein identification.   
Endotoxin testing 
Recombinant proteins were assayed for endotoxin using the manufacturer’s 
instructions for two commercially available kits (Genscript and Pierce). 
RESULTS 
 
Enhanced immunogenicity in cultures from 5% O2 is TLR2-mediated.  
 Increased adjuvant activity in glioma lysates from 5% O2 cultures led to the 
hypothesis that glioma cell culture in physiologic oxygen enriches for DAMPs that 
activate PRRs on DCs (133, 135), and that loss of the cognate PRR should therefore 
eliminate the benefit of vaccines from 5% O2 cultured tumor cells.  TLR2 is a PRR 
implicated in inflammation following hypoxia in the brain and kidney (200-202).  To 
determine if TLR2 is required for recognizing DAMPs we measured CD8 T cell 
responses in the setting of Tlr2 deficiency.  Tlr2-/- splenocytes were unable to enhance 
cross priming in vitro after addition of lysate from 5% O2 (Fig. 4.1A), and vaccination of 
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glioma-bearing Tlr2-/- mice with lysate from 5% O2 failed to eliminate tumor cells (Fig. 
4.1B) or improve survival (Fig. 4.1C).  These data strongly suggest that TLR2 recognizes 
a DAMP that is expressed on glioma cells cultured in 5% O2. 
Monomeric and not tetrameric annexin II exerts adjuvant activity through TLR2   
To identify the putative DAMPs responsible for increased vaccine efficacy, we 
screened glioma lysates for TLR2 binding molecules using immunoprecipitation and 
mass spectrometry.  We found the phospholipid binding protein annexin II (ANXA2) was 
enriched in the TLR2-binding fraction from 5% O2 tumor cell cultures (Table 4.1 and Fig. 
4.2A).  Enrichment of ANXA2 in 5% O2 (Fig. 4.2A), as well as 2% and 1% O2 (Fig. 
4.2B), was confirmed. Binding of ANXA2 and TLR2 was confirmed by co-
immunoprecipitation (Fig. 4.2C).  ANXA2 is one of thirteen annexin family proteins that 
bind negatively charged phospholipids and share 4-6 repeats of “annexin fold” domains 
(203).  ANXA2 exists in cells as a monomer (ANXA2m) or a heterotetramer (ANXA2t) 
of two monomer molecules bound by two molecules of S100A10 (204).  To determine if 
one or both forms bound TLR2, we pulsed ANXA2m and ANXA2t onto Tlr2-transfected 
reporter cells and measured activation by the secretion of alkaline phosphatase (Fig. 4.3 
A).  The results demonstrate that TLR2 signaling was induced exclusively by ANXA2m 
(Fig. 4.3A).  Reporter cells transfected with Tlr7 were not stimulated by ANXA2m or 
ANXA2t (Fig. 4.3B), demonstrating specificity to TLR2.  We next tested whether the 
absence of TLR2 would affect cross priming.  Wildtype and Tlr2-/- mice underwent 
sequential daily vaccination (198) with ovalbumin protein, with or without ANXA2m.  
Wildtype mice receiving ANXA2m in addition to ovalbumin had a two-fold increase in 
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the percentage of circulating antigen-specific CD8 T cells compared to vaccination with 
antigen alone (Fig. 4.3C). However, Tlr2-/- mice were unable to expand the population of 
antigen-specific CD8 T cells above the levels generated by antigen-only vaccination (Fig. 
4.3C).  
 Since TLR2 also binds lipopolysaccharide, we sought to determine whether the 
responses generated in cell culture were endotoxin-related.  We compared levels of TLR2 
signaling induced by sampled of ANXA2 and of annexin V (ANXA5) that contained 
equivalent endotoxin levels (0.65 Endotoxin Units/µg protein; Fig. 4.4A).  Equal 
concentrations of ANXA5 failed to induce TLR2 activity (Fig. 4.3A).  TLR2 signaling 
was also eliminated by exposure of ANXA2m to proteinase or heat (Fig. 4.4B), 
indicating that immunologic activity originated from a protein and not endotoxin.  These 
findings argue that ANXA2m is a unique DAMP in glioma cultures that increases in 
physiologic 5% O2 and boosts cross priming.  
Annexin II is required for immunogenicity  
 
 To determine if the enhanced cross priming responses are due solely to the 
upregulation of ANXA2 and not other molecules induced by 5% O2, we compared 
responses from wildtype GL261 cells with those from a stable ANXA2 knockdown line 
(Fig 4.5A) (199). Knocking down ANXA2 significantly decreased the expansion of 
antigen-specific CD8 T cells in healthy tumor-free mice (Fig. 4.5B) and completely 
ablated any survival benefit of vaccination in glioma-bearing animals (Fig. 4.5C).   
Therefore, we next asked whether the addition of ANXA2m to DC cultures could 
increase cross priming.  To address this question, splenic DCs were pulsed with antigen 
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and glioma lysate from cells cultured in atmospheric (20%) O2, with or without 
ANXA2m.  The addition of ANXA2m significantly increased surface levels of peptide—
MHC I complexes to levels equivalent to those achieved by lysates from 5% O2 (Fig. 
4.6A).  In support of the hypothesis that ANXA2m signals through TLR2, splenic DCs 
from Tlr2-/- mice did not show enhanced levels of OVA antigen-class I complexes 
following stimulation with lysates from 5% O2 or ANXA2m (Fig. 4.6B).  Moreover, 
ANXA2m induced robust maturation of bone marrow-derived dendritic cells as 
evidenced by a significant increase in the surface expression of the co-stimulatory 
molecules CD80 and CD86 (Fig. 4.7A) and secretion of cytokines IL-12p70 and TNF  
(Fig. 4.7B).   
 To determine if the addition of ANXA2m could enhance CD8 T cell function, 
splenocytes were pulsed with antigen and glioma cell lysate from cells cultured in 
atmospheric O2, with or without ANXA2m.  The addition of ANXA2m boosted IFNγ 
production by more than eight-fold (Fig. 4.7C), indicating further that ANXA2m has the 
potential for improving cross priming against tumor antigens. Moreover, the addition of 
ANXA2m to the vaccines extended survival in the EMT6 breast carcinoma model (Fig. 
4.8A).  
To assess the therapeutic potential of ANXA2 expressed within mammalian cells, 
we established a transfectoma cell line from murine NS0 plasmacytoma cells, forcing the 
expression of high levels of ANXA2.  An empty vector transfectoma was used as a 
control.  While 10% of plasmacytoma-bearing animals responded to vaccination with 
empty vector cell lysate, 80% of animals receiving ANXA2-transfected cell lysate had 
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long-term tumor control with no evidence of disease (Fig. 4.8B).  Surprisingly, however, 
addition of ANXA2m to GL261 lysate from 20% O2 cultures failed to increase survival, 
even in the presence of CpG (Fig. 4.9). Taken together, these data indicate that ANXA2m 
can be used as an adjuvant in various cancers.  
Annexin II purified from mammalian cells fails to mature dendritic cells 
 Annexin II was then isolated from NS0 cells in an endotoxin-free environment 
(Fig 4.10A); however immune activity was not observed upon isolation (Fig 4.10 B).  
Circular dichroism measurement of isolated annexin II in the presence and absence of 
calcium was classical for alpha-helical structure, suggesting secondary folding was in 
place (Fig. 4.10 C).  Isolation was performed in cells cultured in 5% O2, in the presence 
of basal epidermal growth factor and fibroblast growth factor, and in the presence of 3-
[(3-Cholamidopropyl) dimethylammonio]-1- propanesulfonate (CHAPS) detergent.  
While all isolations were successfully confirmed by Coomassie staining of PAGE 
products, none successfully activated TLR2, and those tested in vivo did not increase 
cross priming (data not shown).   
Annexin II is enriched in human and canine tumor cells 
Murine and human annexin II and TLR2 exhibit 98% and 74% amino acid 
sequence homology, respectively (205).  Based on these homologies, we asked if 
ANXA2m had the same adjuvant activity in a human CD8 T cell cross-priming assay. 
Given our previous studies demonstrated that human glioma lysates from tumor cells 
cultured in 5% O2 enhance antigen-specific CD8 T cell responses (133), we first tested if 
ANXA2 was upregulated in human glioblastomas cultured in 5% O2.  Expression of 
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ANXA2 was enchanced in 5% O2 cultures (Fig. 4.11A).  In addition, three canine 
meningioma cultures from Chapter Three showed enrichment of ANXA2 in 5% O2 
culture (Fig. 4.11B), indicating the upregulation of this DAMP occurs in two additional 
species and in meningiomas.   
Annexin II monomer enhances activation of human CD8 T cells 
 
 We then tested whether ANXA2 can increase activation of human antigen-
specific CD8 T cells.  Therefore, we pulsed monocyte-derived dendritic cells from 
cytomegalovirus (CMV)-positive and -negative donors with a maturation cocktail and the 
pp65 CMV antigen in the presence or absence of ANXA2m (133, 206).  The addition of 
patient-matched PBMCs led to a ten-fold increase in IFNγ production following 
ANXA2m addition, indicating the potential for ANXA2m to augment cross priming in 
human patients (Fig. 4.11C).   
Development of an annexin II—antigen fusion vaccine 
 These studies provide substantial evidence that ANXA2 is an immunologically 
significant component of tumor cell vaccines.  Aside from cell-based vaccines, many 
clinical trials have been developed that utilize synthesized tumor peptide antigens (207).  
In particular, peptide fusion vaccines show the advantage of increasing uptake and cross 
priming compared to mixtures of unfused molecules (208, 209).  The full-length ANXA2 
protein is not feasible for these types of preparations, so we sought to determine if a 
fragment of ANXA2 could be made that would boost immunogenicity in peptide 
vaccines.  It is known that the annexin repeat regions of ANXA2 are shared with other 
annexin family members such as annexin V (203), which failed to activate TLR2 (Fig. 
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4.2A) or increase cross priming (data not shown).  In contrast, the N terminus of ANXA2 
is unique to this protein (203).  The 15 N terminal amino acids were capable of enhancing 
cross priming in a Tlr2-dependent manner (Fig. 4.12 A).  Further, we synthesized an 
ANXA2 N terminal-SIINFEKL-based fusion peptide and pulsed this fusion onto Tlr2-
transfected reporter cells. The ANXA2 N terminal-OVA antigen fusion protein exhibited 
potent TLR2 activation (Fig. 4.12B).  We then vaccinated mice with equimolar amounts 
this fusion peptide or peptides with equal amounts of antigen, but lacking the 15 N 
terminal amino acids or scrambled N termini amino acids.  These experiments 
demonstrate that the covalent linkage of an antigen with the N terminal fragment peptide 
of ANXA2 allowed for the expansion of antigen-specific CD8 T cells (Fig. 4.12C).  
 
DISCUSSION 
 
Unlocking the cross priming potential of the dendritic cell is a cardinal 
requirement of tumor cell vaccines.  Patient-derived immune suppression or poor 
immunogenicity of cell lysates can limit the impact of co-delivered synthetic adjuvants 
thereby diminishing dendritic cell activation and cross priming.  Our previous studies 
showed how to overcome poor immunogenicity of glioma cell lysates by maintaining 
cells for vaccination in 5% oxygen (135).  This current study demonstrates that 5% 
oxygen induced the upregulation of annexin II monomer (ANXA2m), a previously 
unknown DAMP, in glioma cell cultures. We also found that AXNA2m on glioma cells 
signals through TLR2 resulting in enhanced cross presentation, costimulation and 
cytokine release. Knocking down the expression of annexin II from tumor cells cultured 
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in 5% oxygen led to a loss of adjuvant activity, validating that this DAMP is required for 
increasing cross priming of glioma antigens.  
 We were unable to purify immunologically active ANXA2 from mammalian 
(NS0) cells.  While we are unable to explain the reasons behind this lack of activity, we 
confirmed that the protein was still in solution through circular dichroism.  One of many 
possible post-translational modifications to annexin II may be required for activity that 
may not have been present in the various isolation conditions attempted.  SDS-PAGE 
strongly suggests that post-translational modifications are not present or required in 
lysates from 5% O2, given that there is no band height difference between GL261 lysate 
from 5 and 20% O2.  However, it is possible that modifications that are sensitive to 
reducing conditions are required.  Moreover, mild reducing conditions result in failure of 
recombinant annexin II to migrate at all in SDS-PAGE, with congestion in the loading 
well.  Repeating survival experiments or cross priming experiments using NS0 
transfectomas that express ANXA2 truncations would further strengthen the case that 
immunologic activity is ANXA2-derived. 
Reducing tissue culture O2 to 5% enhances the immunogenicity of glioma lysates 
without compromising the growth or viability of cells (data not shown and refs (133, 
135).  Regulating the concentration of oxygen in tissue culture is straightforward, 
compatible with almost all cell vaccine strategies, and has been applied in many studies 
(133, 135, 210) including two clinical trials (NCT01171469, NCT01400672).  
Decreasing the concentration of oxygen in glioma cultures could easily precede 
additional strategies of inducing of DAMP exposure or release through chemical or 
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radiation-induced injury immediately before harvest.  Additional preclinical studies 
should assess the potential for ANXA2 to synergize with the DAMPs released by these 
means.  
Oxygen sensors and ANXA2 are expressed in essentially all cells (145).  
Immunogenicity may therefore be improved in other tumor cell cultures through ANXA2 
upregulation, either by oxygen regulation or other means.  In addition to murine and 
human gliomas, we observed ANXA2 enrichment in primary canine meningioma (data 
not shown), an aggressive and uniformly fatal brain tumor in dogs (210).  Meningiomas 
cultured in 5% oxygen for vaccine production resulted in a median survival of 645 days 
compared to 220 days without vaccination (210) supporting the broad applicability of this 
model.   
This study also provides further support for the development of specific antigen 
peptide vaccines for cancer immunotherapy.  We have identified the TLR2-active domain 
of ANXA2m and synthesized an ANXA2-antigen fusion peptide.  Fusion of antigens 
with TLR agonists, as opposed to co-delivered but unlinked antigen and adjuvant, 
generate enhanced immune responses by ensuring that DCs and other leukocytes 
encounter both structures simultaneously (208, 209).  ANXA2-antigen fusion peptides 
could be developed for patients as “off-the-shelf” agents containing common tumor 
antigens. Alternatively, they could be “personalized” and synthesized after tumor 
sequencing to identify immunogenic tumor-specific neo-antigens.  As the N terminal 15 
amino acids of ANXA2 are required and sufficient to stimulate TLR2 activity, a fusion 
peptide could be as short as 30 amino acids if one or two CD8 T cell epitopes are fused to 
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the ANXA2 portion.  Future work will address the efficacy of ANXA2 peptide fusions 
alone and in combination with established TLR agonists to induce synergy in preclinical 
models of glioma as observed in other vaccines (211). 
These studies leave open the question of ANXA2 as a potential DAMP in vivo.  
ANXA2 expression is elevated in many tumors (145), and multiple myelomas expressing 
high levels of ANXA2 have a worse prognosis (212).  These data suggest that 
immunogenic activity is absent or is overridden by other potentially tumor-promoting 
functions of ANXA2 (199, 213-215), or by tumor-derived immune suppressive 
mechanisms such as regulatory T cells or myeloid-derived suppressor cells (54, 216).  It 
is also possible that ANXA2m is not present in great enough quantities, is sequestered, or 
exists in its tetrameric form that does not bind TLR2.  The future may bring novel 
approaches to increase the immunogenicity of ANXA2 within tumor cells as a strategy to 
increase anti-tumor immunity in vivo. 
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Figure 4.1 Enhanced immunogenicity in cultures from 5% O2 is TLR2 mediated.  A, 
splenocytes were pulsed with the human gp10025-33 peptide, with or without GL261 
lysate from 5% or 20% O2. Addition of purified pmel CD8 T cells resulted in interferon 
gamma secretion after 48 h. The experiment was repeated three times with similar results. 
B, GL261 glioma-bearing mice were given weekly intradermal vaccination of lysate from 
5% O2 culture and CpG ODN, and activated caspase was assessed by 
immunohistochemistry in tumors at the moribund state. C, survival plot of GL261 
glioma-bearing mice given weekly intradermal vaccination of lysate from 5% O2 culture 
and CpG ODN. Lines indicate p<0.05 by unpaired t-test, and **, p<0.01 by log-rank test. 
A 
B C 
** 
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ENRICHED IN 20% O2 ENRICHED IN 5% O2 
Heat shock protein 9 
(73kDa) 
Histone cluster 1, H1c (21kDa) 
  3-phosphoglycerate dehydrogenase (57 kDa) 
  Serum albumin precursor UPS (69 kDa) 
  Protein disulfide isomerase associated 3 (57 kDa) 
  Ribosomal protein S2 (31kDa) 
  Histone cluster 1, H1b (23 kDa) 
  Histone cluster 1, H1e (22kDa) 
  
Chaperonin containing Tcp1, subunit 3 (gamma)  
(61 kDa) 
  Ribosomal protein SA (33 kDa) 
  Ubiquitin-activating enzyme E1 (118 kDa) 
  Annexin A2 (39 kDa) 
Table 4.1: Proteomic hits of TLR2 binding proteins in GL261 lysate. List of proteins 
identified through LC/MS. Proteins were filtered for those with two or more peptides 
detected, and identity greater than 90% as determined by Scaffold mass/charge ratio 
matching. 
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Figure 4.2: Enrichment of annexin II in GL261 cells cultured in four oxygen 
concentrations. A&B, GL261 cells were cultured in the indicated oxygen concentrations 
for two weeks, and aliquots were taken for vaccination and half of each aliquot was flash-
frozen and blotted for ANXA2 and beta actin as a loading control. C, ANXA2 in GL261 
lysates from 5% O2 culture, co-immunoprecipitated with TLR2 as shown by western 
immunoblot.  Recombinant murine ANXA2 and TLR2 were used as controls. 
 
 
 
A 
B 
C 
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Figure 4.3: ANXA2 monomer increases cross priming through TLR2.  Compounds 
were pulsed onto A, hTLR2- and B, hTLR7-expressing HEK293 Blue® cells, and 
secreted alkaline phosphatase was measured.  C, naïve mice were vaccinated with four 
sequential daily injections or ovalbumin, with or without recombinant human ANXA2 
and boosted once, after three days. Staining of peripheral blood was performed one day 
after the boost. The experiment was replicated twice with similar results. Bars denote 
p<0.005 by unpaired t-test. 
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Figure 4.4: ANXA2 monomer activity is protein-derived. ANXA2 monomer activity 
is protein-derived and induces dendritic cell maturation. A, endotoxin levels were 
quantified using a Limulus amebocyte lysate kit following the manufacturer's instructions 
(Genscript). B, ANXA2m and other compounds were exposed to 2 mg/mL proteinase K 
overnight at 37C or boiling water for 1 hour. Undigested ANXA2m was kept at 37C 
overnight as a control. Compounds were pulsed onto hTLR2-expressing HEK293 Blue® 
cells.  
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Figure 4.5: ANXA2 is required for adjuvant activity and survival benefit of lysates 
from physiologic O2.  A, immunoblot confirming knockdown maintenance in 5% O2.  B, 
naïve mice were vaccinated with four sequential daily injections or ovalbumin, GL261 
lysate from two sub-lines, and CpG 685, and boosted once, three days later (n=8, except 
n=5 for ovalbumin + CpG). Bar shows p<0.005 by unpaired t-test. C, Kaplan-Meier plot 
of weekly vaccination of orthotopic GL261-bearing mice with vaccines from two 
sublines maintained at physiologic O2, with CpG 685 ODN (n=30 saline, n=28 5% O2 + 
CpG, n=10 5% O2 shANXA2 + CpG). ** p<0.0001 by log-rank test.   
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Figure 4.6: ANXA2 is capable of enhancing cross presentation in the presence of 
poorly immunogenic lysates. A&B, splenocytes were pulsed with the OVA248-274 
peptide. The SIINFEKL epitope was detected 24 hours later by flow cytometry using an 
antibody against SIINFEKL/H-2Kb. Data represent cells within a CD11c+MHCII+ gate, 
and lines represent p<0.002.  
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Figure 4.7: ANXA2m induces dendritic cell maturation and increases cross priming. 
A, bone marrow dendritic cell cultures were pulsed with 2.5 µg/mL commercial 
recombinant human ANXA2m or media. Cells were harvested and stained after two days. 
Graphs indicate the CD11c+MHCIIhi gated population. B, supernatant from A was 
collected and assayed using a cytometric bead array. Lines indicate P<0.01 by unpaired t-
test.  C, splenocytes were pulsed with human gp10025-33, with or without GL261 lysate, 
with or without ANXA2, followed by addition of pmel CD8 T cells.  Bars signify p<0.05 
by unpaired t-test.   
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Figure 4.8: ANXA2 is capable of extending survival in the presence of poorly 
immunogenic lysates.  A, Kaplan-Meier survival plot of EMT6 mammary carcinoma-
bearing mice vaccinated with the indicated agents (n=18 saline, n=17 20% O2 lysate + 
CpG, n=10 20% O2 lysate + ANXA2m). * p<0.01 by log-rank test.   B, vaccination of 
mice bearing NS0 plasmacytomas with lysates from cells containing an empty vector or 
an ANXA2-expression vector (n=10 per group). ** p<0.005 by log-rank. 
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Figure 4.9: ANXA2m fails to extend survival in a murine model of malignant 
glioma. Orthotopic GL261-bearing mice were vaccinated weekly as in Figures 4.1 and 
4.3, but with lysate from atmospheric oxygen, CpG ODN, with or without commercial 
ANXA2m. Saline was given as a control, and p=0.83 by log-rank analysis.   
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Figure 4.10: Purified ANXA2m from mammalian cells does not induce dendritic cell 
maturation.  A, Coomassie-stained reducing SDS-PAGE of A2 isolation from ANXA2-
expressing (A2+) and empty vector-expressing (A2-) NS0 cell lysates from 20% oxygen. 
B, bone marrow-derived dendritic cell cultures were pulsed with 10 µg/mL isolate from 
A2+ or A2- cells, LPS, or media. Cells were harvested and stained after two days. Graphs 
indicate the CD11c+MHCIIhi gated population. C, circular dichroism of purified ANXA2  
in the presence of calcium, indicating alpha helical structure.  
A 
B C 
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Figure 4.11: ANXA2 enrichment and activity across species. A, western immunoblot 
of a primary human glioma strain cultured in physiologic 5% or 20% O2 with anti-human 
ANXA2. B, primary meningioma cultures from three dogs were kept in 5% or 
atmospheric (~20%) O2 for two weeks, cells were harvested, and lysates were separated 
by SDS-PAGE and probed for ANXA2 and beta actin as a loading control. C, monocyte-
derived dendritic cells from CMV sera-positive and –negative HLA-A0201+ donors were 
pulsed with the pp65495-503 peptide, with or without ANXA2 monomer. After a day cells 
were washed and autologous PBMCs were added for an additional two days. Interferon 
gamma was measured by bead array. Bars show p<0.01 by unpaired t-test. 
A 
B 
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Figure 4.12: N terminal peptides of ANXA2 increase cross priming through TLR2. 
A and C,  naïve mice were vaccinated with the sequential daily injection protocol, with 
ovalbumin, with or without the ANXA2 15 amino acid peptide or the A2OVA fusion 
peptide and derivatives. B, peptides of the N-terminus of ANXA2 (ANXA2-OVA fusion, 
ANXA2-OVA lacking -p11 binding domain, and scrambled ANXA2-OVA fusion) were 
pulsed onto hTLR2 HEK 293 Blue® cells and secreted alkaline phosphatase was 
measured. Bars represent an unpaired t-test at p<0.05. 
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CHAPTER FIVE 
FINAL DISCUSSION AND FUTURE DIRECTIONS 
Contributions and Synthesis of Study Findings  
 Glioma and recurrent meningioma are two intracranial neoplasms with poor 
prognoses.  Vaccination offers hope to induce long-term control of these tumors with few 
collateral side effects.  While current vaccines show some success in clinical trials, we 
may improve response rates further if we harness the immunogenic plasticity of cancer 
cells in tissue culture.  Previous to these studies it was known that glioma lysates from 
5% O2 culture increased dendritic cell cross presentation, CD8 T cell priming, and 
extended survival in tumor-bearing mice.  It was believed that certain adjuvant molecules 
were enriched in 5% O2 culture, but the molecular mechanisms of O2 in immunogenicity 
were unknown.  Highlighted herein are important contributions to our knowledge of brain 
tumor cell vaccines and tissue culture O2.  In addition, connections amongst these 
chapters have led the formation of testable hypotheses for future work. 
 Prior to this thesis, the adjuvant effect of glioma cells from 5% O2 was assumed 
to be dose-dependent, with the potential to improve efficacy in O2 tensions below 5% 
(135).  Chapter Two provides a broader perspective by examining four tensions: 20%, 
5%, 2%, and 1% O2.  Compared to lysates from 5% O2, 2% O2-derived lysates induced 
greater cross presentation, yet those from 1% O2 were equally immunogenic to those 
from 5% O2.  Western immunoblotting revealed that two heat shock proteins, HSPβ-1 
(HSP27) and HSP70 increase dramatically between 2% and 1% O2, which could temper 
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the adjuvant activity of the lysates.  The role of these proteins must also be confirmed by 
additional studies, but some studies suggest that HSP70 could act as an immune 
suppressive molecule through regulatory CD4 T cells (139, 217).  Annexin II (ANXA2), 
which binds TLR2 and increases cross presentation and cross priming, was also analyzed.  
The fact that ANXA2 is further increased from 2% to 1% O2 appears contradictory to the 
observed decreased in cross presentation; however, the activity of ANXA2 may be 
regulated by other mechanisms, for example, through sequestration by a chaperone 
protein such as HSP70.  Lastly in Chapter Two, a glioma survival study demonstrated 
that lysate from 2% O2 failed to increase survival, despite higher levels of ANXA2 than 
those from 5% O2.  These findings suggest further complexity; while ANXA2 can 
overcome suppression from 20% O2-derived lysates, it appears that higher levels of 
ANXA2 in 2% O2 lysates are inactive or over-powered, either by a modification of 
ANXA2 itself, or by other molecules induced by 2% O2.  Further investigation into the 
difference between lysates from 1% or 2% and 5% O2 may lead to new insights into 
important structural modifications to ANXA2 or to discovery of novel immune 
suppressive molecules.  In addition, we must also characterize the impact of ANXA2 on 
the CD4 helper T cell response, the B cell response and other innate anti-tumor responses 
in the future.  The interactions among these responses may shed light on the complex 
relationship between ANXA2 upregulation below 5% O2 and inferior vaccine responses. 
 Findings on the suppressive properties of glioma lysates from atmospheric 
(20%) O2 from Chapters Two and Four suggest areas of future investigation.  In Chapter 
Two, lysates from 20% O2 inhibit cross presentation and cross priming in vitro, and 
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vaccines from 20% O2 culture are no better than saline (135).  Chapter Four shows that 
the suppressive properties of these lysates depend on TLR2 in vitro.  Further, mass 
spectrometry from Chapter Four identified one TLR2-binding protein candidate immune-
suppressive molecule—heat shock protein A9 (HSPA9, or mortalin).  HSPA9 was 
enriched with 100% probability in GL261 lysate from 20% O2 and 0% probability in 
lysate from 5% O2.  Future studies should test the hypothesis that HSPA9 is an immune-
suppressive molecule in GL261 cells from 20% O2.  Lentivirus-mediated HSPA9 
knockdown has been achieved in other murine cells (218) and could be attempted in 
GL261 cells, with the proper lentiviral knockdown controls. This and other loss-of-
function approaches should be used to assess the role of HSPA9 in immune suppression.  
As mentioned previously, CD200 and other putative suppressive molecules must also be 
investigated.  Once we have confirmed the suppressive role of these molecules, future 
studies could seek to find O2 tensions or other means to deplete or prevent expression of 
these molecules in cells harvested for vaccination.  
 Chapter Two also explored the O2 sensors within GL261 cells that initiate the 
shift in immunogenicity.  The mechanisms orchestrating increased immunogenicity are 
mostly unexplored, but with exciting potential for future experiments that could improve 
glioma cell vaccines.  Desferrioxamine (DFX) is a hypoxia-mimetic that chelates iron, 
inactivates prolyl hydroxylases and stabilizes HIF 1α and 2α.  DFX treatment modestly 
increased immunogenicity of GL261 cells from 20% O2 within 48 hours.  The 
concentration and duration of DFX used were thought to induce HIF 2α levels 
comparable to culture in 1% O2 (129).  Given 1% O2 was less effective at improving 
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cross presentation, it is possible that further optimization of DFX dose will enable greater 
immunogenicity.  Despite data indicating DFX can rescue GL261 lysates from immune 
suppression, a clear connection between HIFs and immunogenicity must be established 
by loss-of-function of HIF 1α or HIF 2α in GL261 cells used for lysate production.  If 
either HIF is required for increased immunogenicity, HIF stabilization may be causing an 
increase in annexin II (ANXA2).  As of yet, however, the direct connection between 
HIFs and ANXA2 is not established.  Binding of HIFs to the ANXA2 promoter and other 
gene loci was not observed in MCF-7 breast carcinoma cells on which HIF1α and 2α 
ChIP-seq was performed (219), and no O2-linked regulators of ANXA2 have been 
detected by ChIP-seq of several common cell lines analyzed by the ENCODE project 
(220).  Additional evidence, however, supports the possibility that ANXA2 is indirectly 
regulated by HIFs.  Specifically, osteoblasts upregulate ANXA2 in low O2, and this 
upregulation can be recapitulated in atmospheric O2 by exposing cells to VEGF, a known 
HIF-regulated protein (142).  If a clear connection does exist between HIFs and ANXA2 
expression, HIF knockdown should also result in decreased expression of ANXA2, and 
loss of immunogenicity in the absence of HIFs should be rescued by ANXA2 
overexpression.  These and further experiments may shed new light on the mechanisms 
of immunogenicity that are switched on within glioma cells cultured in 5% O2. 
 The general applicability of these findings to other tumor cell types is warranted 
from these studies.  While preliminary experiments suggest that not all cell types respond 
to low O2 culture by upregulating ANXA2 and increasing immunogenicity (data not 
shown), these data were collected when 5% O2 incubators were exposed frequently to 
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atmospheric O2 by incubator door opening by other scientists.  Such interruptions in 5% 
O2 culture have been shown by western blot to be correlated with lower ANXA2 
expression in GL261 cells.  In contrast, when GL261 cells are harvested on Mondays, 
after a weekend of uninterrupted 5% O2, they express higher levels of ANXA2 (data not 
shown).  The findings of Chapter Two also present the possibility that various tumor cell 
cultures, perhaps even gliomas from different patients, could have different 
immunogenically optimal O2 tensions.  The clear path to establishing whether these 
findings are more widely applicable is through empiric screening of many tumor cell 
types and primary cultures from multiple patients. 
 High-grade meningioma has no standardized salvage treatment after re-
operation, nor is there an established meaningful model of high-grade disease.  
Vaccination is potentially a powerful strategy for salvage therapy, but prior to this thesis, 
it had not been attempted due to a lack of meaningful model.   Chapter Three tests 
autologous lysate vaccination for spontaneous canine meningioma, a uniformly fatal 
tumor that is a faithful model of aggressive human meningiomas.  Primary meningioma 
cultures were maintained at 5% O2, which enriched for ANXA2 compared to cultures 
from 20% O2.  Vaccination of dogs extended survival more than three-fold compared to 
historic controls.  Based on relative enrichment of ANXA2, we would have expected 
strong cross priming responses; however, dogs had robust humoral responses against 
their tumors and rare T cell responses.  Antibodies raised from vaccination recognized 
other meningiomas from other study dogs and one human.  These antibody responses 
were capable of antibody-dependent cell-mediated cytotoxicity.  While a direct 
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comparison with 20% O2 lysate vaccination is needed to make firm conclusions on O2’s 
influence on vaccine efficacy, these results indicate that robust induction of antibody 
responses was induced by vaccines from 5% O2.  In contrast, in murine glioma studies, 
vaccination with lysate from 5% O2 augmented CD8 T cell responses and decreased 
clonality of tumor-reactive antibody responses (135).  
 Many potential mechanisms could explain the apparent dominance of the B cell 
and antibody response and minimal T cell response in dogs vaccinated for meningioma, 
versus mice vaccinated for glioma.  First, PBMC samples from dogs were collected two 
weeks after the most recent vaccination, which is after the contraction of the T cell 
response in mice and humans (221, 222).  In addition it is known that antigen dose can 
impact the timing and extent of the CD8 T cell response (221).  The normalized canine 
vaccine dose was dramatically lower than that of mice in the O2 glioma studies (0.02 
versus 3.65 mg/kg) (135, 210).  Therefore proliferation may have ceased before large 
numbers of tumor-reactive cells reached a detectible frequency in the blood.  It is also 
possible that meningioma-reactive CD8 T cells were present in other tissues but not the 
blood.  Postmortem samples were analyzed by immunohistochemistry (IHC) following 
death in glioma-bearing mice and dogs treated for meningioma.  Dogs in the meningioma 
study had an abundance of B and plasma cells, with mild T cell infiltrates, arguing 
against the theory that the T cells were more abundant in other tissues than the blood.  In 
contrast, in the murine publication that first described the benefit of vaccines from 5% 
O2, glioma-bearing mice were euthanized at a moribund state and stained for CD3.  These 
mice were not assayed for B cells; however, mice receiving similar vaccines have shown 
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B cell and plasma cell infiltration, and a dependence on B cells for vaccination (Murphy 
et al., in preparation).  Another potential explanation for the differences in relative T and 
B cell responses seen by IHC could be that there was essentially no tumor burden in the 
dogs that were examined, while there was extremely high tumor burden in the mice.  
Though one would expect that both B and T lymphocytes would increase in the presence 
of increased antigen, the relative influx of cells may be more similar if antigen loads were 
more comparable between these two models.   
 Expression of TLRs likely plays a role in the perceived differential vaccine 
response between mice and canines to CpG, ANXA2, and imiquimod.  Whereas TLR2, 
the receptor for ANXA2, is expressed broadly in murine cells, including lymphocytes, it 
is expressed on canine granulocytes, monocytes, and a minor but as-of-yet unidentified 
sub-population of lymphocytes (223, 224).  Murine TLR7 and 9 (which sense imiquimod 
and CpG respectively) are expressed in myeloid lineage cells (225), including most 
dendritic cells, canine TLR7 expression is not known, and TLR9 is expressed on canine 
granulocytes, monocytes, and all lymphocytes (224).  Peptide sequence of annexin II, 
TLR2, TLR7, and TLR9 suggest that the molecular interactions of receptor and ligand 
are similar.  Peptide sequence homology of annexin II is highly similar among human, 
dog, and mouse (99% and 98% homology to human, respectively) (205).  Likewise, dog 
and mouse TLRs 2,7, and 9 are 67%, 79%, and 75% homologous, respectively (205).  
While homology comparisons may give a rough picture of the relative similarity is 
responsiveness to a given ligand, empiric comparisons must be carried out to determine if 
the quality of the responses truly differ.  Further testing of many cytokines and cell 
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responses under equal experimental conditions would have to be done to draw 
comparative conclusions.    
 Despite unclear explanations for the differences between murine glioma and 
canine meningioma studies, the successful outcomes in this canine study could lead to 
identification of relevant meningioma antigens and potential damage-associated 
molecular patterns (DAMPs).  One antigen recognized by post-vaccination antibodies in 
dogs was HSP60.  A previous study reported an upregulation of HSP60 upon hypoxia in 
the brain (226).  While this study suggests HSP60 may be enriched in 5% O2, our blotting 
of HSP60 in GL261 cells cultured in four O2 tensions did not show significant O2 
dependence.  The significance of HSP60 is unknown, and further loss of function and 
gain of function cross priming studies need to be carried out in GL261 cells to make 
definitive conclusions.  Moreover, further antigen identification will be investigated from 
dogs vaccinated for meningioma, using pre- and post-vaccination sera combined with 
molecular analysis that provides hints as to the more tumor-specific antigens for targeting 
in the future.   
 Prior to these thesis studies, the molecules responsible for the enhanced 
immunogenicity of glioma cells from 5% O2 were unknown.  Chapter Four characterizes 
the annexin II monomer (ANXA2m) as a key DAMP responsible for increased 
immunogenicity of lysates from 5% O2.  Proteomic comparisons of whole glioma lysate 
from 20% and 5% O2 would generate overwhelmingly large numbers of candidates to test 
manually.  Therefore, a crucial advance came when vaccination was found to be 
ineffective in hosts null for Tlr2.  Immunoprecipitation of TLR2-binding molecules in 
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GL261 lysates therefore enabled distillation to a small list of candidate DAMPs, 
including ANXA2.  Purified recombinant ANXA2m bound and activated TLR2, unlike 
the ANXA2t, strongly suggesting that ANXA2m operated in lysates from 5% O2.  
Knocking down ANXA2 in GL261 cells led to vaccine failure, indicating ANXA2 was 
required for the efficacy of vaccines from 5% O2.  ANXA2 increased cross presentation, 
cross priming, and survival of tumor bearing animals when combined with poorly 
immunogenic lysates from atmospheric O2, suggesting a dominant effect over putative 
immune-suppressive molecules.  Patient glioma cultures also upregulated ANXA2 in 5% 
O2 and showed profound stimulatory activity when ANXA2 was covalently linked to 
antigen for cross priming.   
 Following several observations, the immune active domain of ANXA2m was 
pinpointed to the N terminus through synthesis of N terminal peptide fragments.  Binding 
of TLR2 and enhanced cross priming were accomplished with the 15 N terminal peptides 
of ANXA2, making feasible synthesized peptide vaccination.   Since covalent linkage of 
adjuvant with antigen has improved immune responses in several systems (208, 209), the 
N terminus of annexin II was linked to a CD8 T cell epitope of chicken ovalbumin as a 
proof-of-principle.  Following identification of relevant peptide epitopes, off-the-shelf 
brain tumor vaccines may be synthesized, as peptide fusions with the N terminus of 
ANXA2.  
 Additional putative DAMPs were enriched in a proteomic screen of TLR2-
binding proteins enriched in 5% O2.  Further studies must be carried out to investigate the 
roles of these proteins.  A logical progression would be similar to that taken during 
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investigation of ANXA2: confirm enrichment and binding by immunoblot, followed by 
testing the requirement of such molecules for immunogenicity, then ability to gain 
immunogenicity upon addition of isolated protein.  Given that knockdown of ANXA2 
eliminated all survival benefit from vaccination with lysate from 5% O2, it is unlikely that 
other proteins will induce a sufficient gain of function upon addition of other putative 
DAMPs to vaccines with lysate from atmospheric O2.  Such evidence suggests that 
ANXA2 is dominant within this system.  
 From a translational perspective, immunoblots of ANXA2 in canine 
meningiomas highlight inter-tumor heterogeneity among tumors in 5% O2.  ANXA2 
levels in three tumors varied greatly, raising the question of whether a standard O2 
tension should be used for culture of cells for vaccination.  One alternative is O2 titration 
of individual tumor cultures to achieve a high enough level of ANXA2 expression.  
Given the results of Chapter Two, indicating a “sweet spot” in O2 level and 
immunogenicity, empiric murine studies or in vitro assays of canine cell lysates must be 
run to determine which oxygen content yields the most immunogenic lysate among many 
primary tumors.  Immunogenicity should then be traced back to ANXA2 expression and 
perhaps other candidates that could play a key role as players in vaccine efficacy.  
Perspective 
 Cultured tumor cell components are a source of many unidentified patient-
specific antigens and have great potential to prime polyclonal responses.  Whole brain 
tumor cell lysate vaccines can be made immunogenic through various manipulations in 
tissue culture, thus realizing their potential.  These manipulations may enable enrichment 
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and identification of immunogenic molecules or antigens using new knowledge of the 
immune system and the immunogenic mediators within tumor cells.  The seemingly 
infinite array of molecules present within tumor cells is, in fact, large; however, it is 
finite, and better characterization may enable alteration of a small number of relevant 
immunogenic determinants.  We knew previously that decreasing O2 levels in glioma cell 
cultures causes enrichment in adjuvant molecules that increase cross priming.  This thesis 
sought to increase understanding of this effect for more rational design of brain tumor 
cell vaccines and for the potential development of immunogenic structures as purified 
vaccine components in the future.   
 For widespread success in immunotherapy, we will need a number of 
simultaneous approaches.  Tumor cell vaccines have shown great promise when 
combined with immune checkpoint inhibitors to overcome tumor-derived immune 
suppression.  Findings from this thesis and others suggest that we have been introducing 
suppressive factors within tumor cell vaccines, but removal of these factors or addition of 
immunogenic factors can turn the tables for increased efficacy. With proper manipulation 
of O2 and other tissue culture treatments to release other DAMPs, brain tumor cell 
vaccines could increase patient survival.  
 This thesis exemplifies the importance of not simply understanding the tumor to 
be targeted, or how to best activate the immune system, but how the two entities interact 
to affect disease outcomes.  Increasing knowledge of one’s own immune system will 
reveal new avenues for immune activation and cancer vaccine approaches.  As well, 
increased knowledge of brain tumors and how we can shape their phenotype to our 
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advantage will enable us to better attack them at their weakest points to induce 
immunogenic responses in the tumor in situ.  Knowledge from both sides is indispensible 
for knowing how to bring vaccination with tumor cells into standard neuro-oncology 
practice.  Through the study of how cultured cells can activate the immune system 
through culture-induced conditions, this thesis contributes to both aspects at their 
intersection.   
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